<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE collection SYSTEM "BioC.dtd"><collection><source>BioC-API</source><date>20260212</date><key>collection.key</key><document><id>PMC12854282</id><infon key="license">CC BY-NC-ND</infon><passage><infon key="article-id_doi">10.23922/jarc.2025-071</infon><infon key="article-id_pmc">PMC12854282</infon><infon key="fpage">135</infon><infon key="issue">1</infon><infon key="kwd">inflammatory bowel disease dysplasia colorectal cancer anorectal cancer small bowel cancer guidelines</infon><infon key="license">Journal of the Anus, Rectum and Colon is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).</infon><infon key="lpage">168</infon><infon key="name_0">surname:Ishihara;given-names:Soichiro</infon><infon key="name_1">surname:Tanaka;given-names:Shinji</infon><infon key="name_10">surname:Matsumoto;given-names:Takayuki</infon><infon key="name_11">surname:Watanabe;given-names:Kenji</infon><infon key="name_12">surname:Ikeuchi;given-names:Hiroki</infon><infon key="name_13">surname:Uchino;given-names:Motoi</infon><infon key="name_14">surname:Okita;given-names:Yoshiki</infon><infon key="name_15">surname:Okabayashi;given-names:Koji</infon><infon key="name_16">surname:Koganei;given-names:Kazutaka</infon><infon key="name_17">surname:Sugita;given-names:Akira</infon><infon key="name_18">surname:Takahashi;given-names:Kenichi</infon><infon key="name_19">surname:Hata;given-names:Keisuke</infon><infon key="name_2">surname:Uraoka;given-names:Toshio</infon><infon key="name_20">surname:Higashi;given-names:Daijiro</infon><infon key="name_21">surname:Futami;given-names:Kitaro</infon><infon key="name_22">surname:Matsuda;given-names:Keiji</infon><infon key="name_23">surname:Mizushima;given-names:Tsunekazu</infon><infon key="name_24">surname:Watadani;given-names:Yusuke</infon><infon key="name_25">surname:Kawachi;given-names:Hiroshi</infon><infon key="name_26">surname:Shimoda;given-names:Masayuki</infon><infon key="name_27">surname:Sugai;given-names:Tamotsu</infon><infon key="name_28">surname:Yoshida;given-names:Masahiro</infon><infon key="name_29">surname:Yamaguchi;given-names:Naohiko</infon><infon key="name_3">surname:Saito;given-names:Yutaka</infon><infon key="name_30">surname:Itabashi;given-names:Michio</infon><infon key="name_31">surname:Anzai;given-names:Hiroyuki</infon><infon key="name_32">surname:Kishikawa;given-names:Junko</infon><infon key="name_33">surname:Komatsu;given-names:Koichi</infon><infon key="name_34">surname:Shinagawa;given-names:Takahide</infon><infon key="name_35">surname:Tsushima;given-names:Tatsuya</infon><infon key="name_36">surname:Noguchi;given-names:Tatsuki</infon><infon key="name_37">surname:Okada;given-names:Satoshi</infon><infon key="name_38">surname:Sugihara;given-names:Kenichi</infon><infon key="name_39">surname:Ajioka;given-names:Yoichi</infon><infon key="name_4">surname:Takamaru;given-names:Hiroyuki</infon><infon key="name_5">surname:Nakase;given-names:Hiroshi</infon><infon key="name_6">surname:Naganuma;given-names:Makoto</infon><infon key="name_7">surname:Hisamatsu;given-names:Tadakazu</infon><infon key="name_8">surname:Fujii;given-names:Toshimitsu</infon><infon key="name_9">surname:Matsuura;given-names:Minoru</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="volume">10</infon><infon key="year">2026</infon><offset>0</offset><text>Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2024 for the Clinical Practice of Inflammatory Bowel Disease-Associated Intestinal Neoplasia (English Version)</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>182</offset><text>The number of patients with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), continues to increase in many countries and regions. With recent rapid advances in medical therapies targeting intestinal inflammation, the number of patients with long-term disease duration is also increasing. It is well-recognized that longstanding IBD carries an increased risk of developing gastrointestinal (GI) neoplasia, particularly colorectal cancer. However, compared to sporadic GI tumors, IBD-associated GI tumors are relatively rare, and even among specialists in GI diseases, opportunities to encounter such cases remain limited. </text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>849</offset><text>In light of this situation, the Japanese Society for Cancer of the Colon and Rectum (JSCCR), in collaboration with the Japanese Inflammatory Bowel Disease Research Group (funded by the Japan Sciences Research Grant for Research on Intractable Diseases affiliated with the Ministry of Health, Labour, and Welfare) launched the Guideline Development Committee for IBD-associated Gastrointestinal Tumors in 2021, with the aim of establishing clinical practice guidelines to support the diagnosis and management of these tumors. </text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1375</offset><text>The committee―comprising experts in gastroenterology, surgery, pathology, guideline development, and literature review―conducted extensive discussions and successfully published the first Japanese edition of the guidelines in July 2024. We believe that the current edition provides the best possible guidance based on presently available knowledge. Furthermore, the guideline development process highlighted several key issues to be addressed in future research and clinical practice. </text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1865</offset><text>We are pleased to present here the English version of the JSCCR Guidelines 2024 for the Clinical Practice of IBD-associated Intestinal Neoplasia. </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>2012</offset><text>Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2025</offset><text>The number of patients with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), is on the increase in Japan. It is well known that patients with longstanding IBD have an increased risk of developing gastrointestinal (GI) malignancies. However, the clinicopathological features of IBD-associated tumors often differ from those of sporadic GI cancers, and accordingly, their diagnosis and treatment also differ. Despite this, the current evidence for the diagnosis and treatment of IBD-associated GI neoplasms remains limited compared to that for sporadic colorectal cancer (CRC), and related clinical knowledge has yet to be widely disseminated.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2712</offset><text>In 2021, the Japanese Society for Cancer of the Colon and Rectum (JSCCR) established the Committee for the Development of Guidelines for the Clinical Practice of IBD-Associated Intestinal Neoplasia, in collaboration with the Japanese IBD Research Group funded by the Japan Sciences Research Grant for Research on Intractable Diseases affiliated with the Ministry of Health, Labour, and Welfare. The goal was to create clinical guidelines to support the management of IBD-associated GI tumors. While the amount of evidence available for IBD-associated GI tumors remains markedly limited compared to that for sporadic GI tumors, the committee―comprising experts in internal medicine, surgery, pathology, guideline development, and literature search―engaged in repeated discussions through online meetings and email correspondence under the constraints of the COVID-19 pandemic. As a result of these efforts, we published the first Japanese edition of these guidelines in July 2024, and here we present the English version, focusing on the section addressing Clinical Questions.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>3792</offset><text>Methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>3800</offset><text>Evidence level and strength of recommendations for clinical questions (CQs)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>3876</offset><text>Each recommendation for the CQs includes an assessment of the evidence level and the strength of recommendation based on the methodology described below. When the strength of recommendation could not be determined, this was indicated as “No recommendation grade.” For CQs deemed inappropriate for grading, no strength of recommendation was assigned.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>4230</offset><text>Evidence level for CQs</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>4253</offset><text>Relevant literature for each CQ was collected using the method described in the section “Literature Search Method.” The study designs were categorized, and the evidence for each outcome was evaluated using the GRADE system and the 2020 edition of the Minds Clinical Practice Guideline Development Manual (Table 1, 2 and 3). Final evidence levels were then determined.</text></passage><passage><infon key="file">t001.xml</infon><infon key="id">t001</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>4625</offset><text>Classification of Evidence Levels and Method for Overall Evidence Evaluation.</text></passage><passage><infon key="file">t001.xml</infon><infon key="id">t001</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;th valign=&quot;top&quot; align=&quot;left&quot; style=&quot;border-top:solid thin;&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Step 1 (Evaluation of Individual Studies): Assess study design and risk of bias.&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Step 2 (Overall Evaluation of Multiple Accumulated Studies):&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;① Initial Rating Based on Study Design&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;◦Systematic review, meta-analysis, RCTs → Initial evidence level: A (High)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;◦Observational studies, cohort studies, case-control studies → Initial evidence level: C (Low)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;◦Case series, case reports → Initial evidence level: D (Very Low)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;② Factors for Downgrading Evidence Level&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;◦Presence of risk of bias&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;◦Inconsistency of evidence&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;◦Imprecision of data&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;◦High likelihood of publication bias&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;③ Factors for Upgrading Evidence Level&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;◦Large effect size with no confounding factors&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;◦Presence of dose-response gradient&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;◦Potential confounding factors would likely underestimate the true effect&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>4703</offset><text>Step 1 (Evaluation of Individual Studies): Assess study design and risk of bias.	 	Step 2 (Overall Evaluation of Multiple Accumulated Studies):	 	① Initial Rating Based on Study Design	 	◦Systematic review, meta-analysis, RCTs → Initial evidence level: A (High)	 	◦Observational studies, cohort studies, case-control studies → Initial evidence level: C (Low)	 	◦Case series, case reports → Initial evidence level: D (Very Low)	 	② Factors for Downgrading Evidence Level	 	◦Presence of risk of bias	 	◦Inconsistency of evidence	 	◦Imprecision of data	 	◦High likelihood of publication bias	 	③ Factors for Upgrading Evidence Level	 	◦Large effect size with no confounding factors	 	◦Presence of dose-response gradient	 	◦Potential confounding factors would likely underestimate the true effect	 	</text></passage><passage><infon key="file">t001.xml</infon><infon key="id">t001</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>5531</offset><text>④ Final Overall Evidence Level: Determined by sequentially evaluating the above criteria</text></passage><passage><infon key="file">t002.xml</infon><infon key="id">t002</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>5622</offset><text>Definitions of Evidence Levels for CQs.</text></passage><passage><infon key="file">t002.xml</infon><infon key="id">t002</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th valign=&quot;middle&quot; align=&quot;center&quot; style=&quot;border-top:solid thin;border-bottom:solid thin;&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Evidence Level&lt;/th&gt;&lt;th valign=&quot;middle&quot; align=&quot;center&quot; style=&quot;border-top:solid thin;border-bottom:solid thin;&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Definition&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; style=&quot;border-top:solid thin;&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Level A (High)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; style=&quot;border-top:solid thin;&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;There is high certainty about the expected effect.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Level B (Moderate)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;There is moderate certainty about the expected effect. The true effect is likely to be close to the estimate, but there is a possibility that it is substantially different.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Level C (Low)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;There is limited certainty about the expected effect. The true effect may be substantially different from the estimate.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; style=&quot;border-bottom:solid thin;&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Level D (Very Low)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; style=&quot;border-bottom:solid thin;&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;There is very little certainty about the expected effect. The true effect is likely to be substantially different from the estimate.&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>5662</offset><text>Evidence Level	Definition	 	Level A (High)	There is high certainty about the expected effect.	 	Level B (Moderate)	There is moderate certainty about the expected effect. The true effect is likely to be close to the estimate, but there is a possibility that it is substantially different.	 	Level C (Low)	There is limited certainty about the expected effect. The true effect may be substantially different from the estimate.	 	Level D (Very Low)	There is very little certainty about the expected effect. The true effect is likely to be substantially different from the estimate.	 	</text></passage><passage><infon key="file">t003.xml</infon><infon key="id">t003</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>6243</offset><text>Overall Certainty (Strength) of Evidence.</text></passage><passage><infon key="file">t003.xml</infon><infon key="id">t003</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th valign=&quot;middle&quot; align=&quot;center&quot; style=&quot;border-top:solid thin;border-bottom:solid thin;&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Grade&lt;/th&gt;&lt;th valign=&quot;middle&quot; align=&quot;center&quot; style=&quot;border-top:solid thin;border-bottom:solid thin;&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Definition&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; style=&quot;border-top:solid thin;&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;A (Strong)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; style=&quot;border-top:solid thin;&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;High certainty that the estimated effect appropriately supports the recommendation.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;B (Moderate)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Moderate certainty that the estimated effect appropriately supports the recommendation.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;C (Weak)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Limited certainty that the estimated effect appropriately supports the recommendation.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; style=&quot;border-bottom:solid thin;&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;D (Very Weak)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; style=&quot;border-bottom:solid thin;&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Very little certainty that the estimated effect appropriately supports the recommendation.&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>6285</offset><text>Grade	Definition	 	A (Strong)	High certainty that the estimated effect appropriately supports the recommendation.	 	B (Moderate)	Moderate certainty that the estimated effect appropriately supports the recommendation.	 	C (Weak)	Limited certainty that the estimated effect appropriately supports the recommendation.	 	D (Very Weak)	Very little certainty that the estimated effect appropriately supports the recommendation.	 	</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>6710</offset><text>Strength of recommendations for CQs</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6746</offset><text>Based on the determined evidence levels, draft recommendations were prepared. These drafts were evaluated and discussed by the Guideline Committee. The strength of recommendation was then determined by voting using the GRADE Grid method, considering the following four factors:</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7024</offset><text>① Certainty of evidence</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7050</offset><text>② Patient preferences</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7074</offset><text>③ Balance of benefits and harms</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7108</offset><text>④ Costs</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7118</offset><text>Committee members with conflicts of interest (COI) for a specific CQ were instructed to abstain from voting on that CQ.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7238</offset><text>(1) Each member voted by selecting one of the following five options:</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7308</offset><text>① “Strongly recommend”</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7337</offset><text>② “Weakly recommend”</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7364</offset><text>③ “Weakly recommend against”</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7399</offset><text>④ “Strongly recommend against”</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7436</offset><text>⑤ “No recommendation”</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7464</offset><text>(2) If ≥70% of votes supported one of the five options; it was adopted as the recommendation.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7560</offset><text>If not:</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7568</offset><text>- If the total for ① + ② exceeded 50% and ③ + ④ did not exceed 20%, the result was “Weakly recommend.”</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7683</offset><text>- If ③ + ④ exceeded 50% and ① + ② did not exceed 20%, the result was “Weakly recommend against.”</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7792</offset><text>(3) If neither condition was met in the first round, the result was deemed “No consensus,” and after disclosing the vote result, a second round of discussion and voting was held, considering the Japanese medical context.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8017</offset><text>(4) If consensus could not be reached in the second round either, the recommendation was marked as “No recommendation.”</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>8141</offset><text>Literature search method</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8166</offset><text>For each CQ, a literature search was conducted using PubMed and Ichushi Web to identify articles published between January 1995 and September 2021, in English and Japanese. When necessary, the search strategies were revised.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8391</offset><text>The searches were performed by a medical librarian in collaboration with each CQ's assigned committee member(s), using October 2021 as the reference search date. Relevant guidelines and documents were added through hand-searching and critical appraisal when deemed appropriate.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>8669</offset><text>CQs</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>8673</offset><text>CQ1: What is the definition of IBD-associated GI neoplasia?</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>8733</offset><text>Statement</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8743</offset><text>It refers to epithelial tumors arising from inflamed mucosa in inflammatory bowel disease, excluding those diagnosed pathologically as sporadic neoplasms.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>8898</offset><text>Comments</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8907</offset><text>In UC and CD―collectively referred to as IBD―the incidence of colorectal and small intestinal cancers becomes significantly higher than that of the general population approximately 8-10 years after disease onset. This type of carcinogenesis, occurring in chronically inflamed mucosa, is known as inflammation-associated carcinogenesis. Before the development of inflammation-associated cancer, a variety of factors are thought to contribute, including chronic persistent inflammation due to IBD; infectious agents such as bacteria and viruses; changes in the gut microbiota; inflammatory cytokines such as tumor necrosis factor (TNF)-α and interleukin (IL)-6; endogenous mediators like reactive oxygen and nitrogen species; genetic alterations in tumor-related genes; epigenetic modifications such as DNA methylation; and oxidative stress-induced DNA damage. Inflammation-associated carcinogenesis is believed to begin morphologically with intraepithelial neoplasia called dysplasia, forming a process known as the inflammation-dysplasia-carcinoma sequence.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9970</offset><text>In contrast, it is also possible for tumors to develop in the intestinal mucosa of patients with IBD independently of inflammation, termed sporadic neoplasia. Particularly in elderly patients or those with a short disease duration, lesions such as de novo carcinomas, serrated lesions and their malignant transformations, or sporadic adenomas and their progression to cancer (sporadic carcinoma) may be present via mechanisms different from inflammation-associated carcinogenesis. Strictly speaking, the term IBD-associated GI neoplasia should refer only to tumors arising from inflamed mucosa―that is, inflammation-associated cancers. However, in practice, no concrete diagnostic criteria exist for distinguishing inflammation-associated cancer, and tumors occurring in inflamed mucosa of patients with IBD have historically been treated collectively as IBD-associated GI neoplasms. Since the 1990s, efforts have been made to differentiate between inflammation-associated neoplasms and sporadic adenomas among raised mucosal neoplasms arising from inflamed mucosa in IBD. However, for invasive carcinomas that have penetrated the submucosal layer or deeper, no clear distinction between inflammation-associated and sporadic carcinomas has yet been established.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>11234</offset><text>Therefore, although the term IBD-associated GI neoplasia should ideally be used only for tumors arising from inflamed mucosa, given the current limitations, it is considered practical to define it as all tumors arising in the inflamed mucosa of patients with IBD, excluding those pathologically diagnosed as sporadic mucosal neoplasms (see CQ13 for pathological criteria distinguishing sporadic tumors). Nonetheless, this definition may evolve with future clinical and basic research. One of the future challenges will be the clinical management of sporadic serrated lesions and their malignant transformations.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>11846</offset><text>It is important to note that pathological diagnostic criteria for mucosal neoplasms differ between Japan and Western countries. In Western pathology, intraepithelial (mucosal) neoplasms are generally not diagnosed as carcinoma. In other words, the term “cancer” in Western literature and research refers exclusively to epithelial tumors that have invaded the submucosa or beyond; mucosal neoplasms are classified as either adenomas or dysplasia. In contrast, in Japanese pathology, mucosal neoplasms may be diagnosed as carcinoma in situ (intramucosal carcinoma) based on their degree of cytological atypia. Consequently, Western-diagnosed sporadic adenomas may correspond to adenoma with intramucosal carcinoma or even pure carcinoma without adenomatous components under Japanese diagnostic criteria.</text></passage><passage><infon key="file">t004.xml</infon><infon key="id">t004</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>12652</offset><text>Strength of Recommendations for CQs.</text></passage><passage><infon key="file">t004.xml</infon><infon key="id">t004</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th valign=&quot;middle&quot; align=&quot;center&quot; style=&quot;border-top:solid thin;border-bottom:solid thin;&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Recommendation Grade&lt;/th&gt;&lt;th valign=&quot;middle&quot; align=&quot;center&quot; style=&quot;border-top:solid thin;border-bottom:solid thin;&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Description&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; style=&quot;border-top:solid thin;&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1 (Strong recommendation)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; style=&quot;border-top:solid thin;&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Strongly recommend performing the intervention.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;justify&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Strongly recommend to not perform the intervention.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2 (Weak recommendation)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Weakly recommend performing the intervention.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;justify&quot; style=&quot;border-bottom:solid thin;&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; style=&quot;border-bottom:solid thin;&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Weakly recommend to not perform the intervention.&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>12689</offset><text>Recommendation Grade	Description	 	1 (Strong recommendation)	Strongly recommend performing the intervention.	 		Strongly recommend to not perform the intervention.	 	2 (Weak recommendation)	Weakly recommend performing the intervention.	 		Weakly recommend to not perform the intervention.	 	</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>12981</offset><text>CQ2: What are the risk factors for IBD-associated GI tumors?</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>13042</offset><text>Statement</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_4</infon><offset>13052</offset><text>UC-associated colorectal tumors</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>13084</offset><text>1. Disease duration, extensive colitis type, active inflammation, inflammatory polyps, the presence of primary sclerosing cholangitis (PSC), and family history of colorectal cancer are risk factors for the development of colorectal cancer. (Evidence level B)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>13343</offset><text>2. The presence of backwash ileitis is a risk factor for colorectal cancer. (Evidence level C)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_4</infon><offset>13438</offset><text>CD-associated GI tumors</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>13462</offset><text>1. Small bowel-colon type or colonic type CD is a risk factor for colorectal cancer. (Evidence level B)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>13566</offset><text>2. CD is a risk factor for small intestinal cancer. (Evidence level B)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>13637</offset><text>3. Patients with CD with anorectal lesions are at risk for rectal-anal canal cancer. (Evidence level C)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>13741</offset><text>Comments</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_4</infon><offset>13750</offset><text>UC-associated colorectal tumors</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>13782</offset><text>According to a report by Eaden et al. in 2001, the risk of developing colorectal cancer in UC increases approximately 10 years after diagnosis. It is estimated that the risk is 2% at 10 years, 8% at 20 years, and 18% at 30 years. In contrast, the European Crohn's and Colitis Organization (ECCO) guidelines from 2017 state that recent population-based studies have shown that the incidence risk is lower than before. For example, in a cohort study in New Zealand, 518 patients with UC were followed, with the overall incidence rate being 1.35/1,000 person-years (95% confidence interval: 0.74-2.27). The age-adjusted standardized incidence rate compared to the general population of New Zealand was 1.74 (95% CI: 1.03-2.93). Regarding prognosis, Matsuoka et al. in Japan reported a 5-year survival rate of 89% for UC-associated colorectal cancer, with no significant difference in cases of Stage II or lower when compared to sporadic colorectal cancer, and it is showing an improvement trend with early detection. However, some cohort studies still report poor prognosis, and the results vary by country or region.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>14897</offset><text>The ECCO guidelines and the British Society of Gastroenterology guidelines list risk factors for UC-associated colorectal cancer as long disease duration, endoscopic and histopathological extensive colitis type (no increase in the risk for rectal colitis type), disease activity, inflammatory polyps, family history of colorectal cancer, and PSC co-occurrence. A study combining data from Leuven University and a cohort in The Netherlands attempted to create a scoring system for risk factors for UC-associated colorectal cancer, including the presence of UC, PSC, extensive disease (≥50%), and inflammatory polyps. However, UC-associated colorectal cancer has been reported even in patients with a short disease duration. Cohen-Mekelburg et al. analyzed 93 cases of IBD-associated colorectal cancer at a single institution, finding that 11 (11.8%) developed within 8 years of diagnosis. In Japan, Hata et al. reported that 17% of UC-associated colorectal cancer cases were detected within 8 years of onset. These findings suggest that, instead of relying solely on disease duration, surveillance colonoscopy should consider other risk factors, such as individual patient history, treatment, and the intensity of disease activity.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>16130</offset><text>Regarding UC's backwash ileitis, there are reports stating it increases the risk of colorectal cancer, while others suggest the risk is limited to dysplasia. Although the mechanism is not clear, there are studies suggesting a correlation between backwash ileitis and PSC, which is also associated with an increased cancer risk. Interestingly, appendectomy is known to be protective against the development of UC, but there is a debate as to whether appendectomy might increase the risk of UC-associated colorectal cancer.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_4</infon><offset>16652</offset><text>CD-associated GI tumors</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>16676</offset><text>Although knowledge regarding CD-associated GI tumors is more limited compared to UC-associated colorectal tumors, colonic disease is considered a risk factor for colorectal cancer, similar to UC, and warrants surveillance colonoscopy.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>16911</offset><text>In cohort studies from Sweden and Denmark, they compared 47,035 patients who developed CD between 1969 and 2017 with a control group of 463,187 individuals adjusted for sex, age, and other factors. Among patients with CD, 296 (0.47 per 1,000 person-years) died from colorectal cancer, while 1,968 (0.31 per 1,000 person-years) did in the control group, resulting in an overall adjusted hazard ratio (HR) of 1.74 (95% CI: 1.54-1.96), indicating a higher colorectal cancer mortality rate in patients with CD. A meta-analysis by Canavan et al. showed the relative risk of colorectal cancer for all patients with CD was 2.5 (95% CI: 1.3-4.7), 4.5 (95% CI: 1.3-14.9) for colonic disease, and 1.1 (95% CI: 0.8-1.5) for ileal disease. Cumulative risk analysis showed that the relative risk for colorectal cancer 10 years after CD diagnosis was 2.9 (95% CI: 1.5-5.3), with a decreasing trend over the past 30 years. In contrast, the relative risk of small intestinal cancer in CD was 33.2 (95% CI: 15.9-60.9), and while the risk of colorectal cancer has decreased, the relative risk of small intestinal cancer has not shown a significant decline over the past 30 years.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>18073</offset><text>In a cohort study in France, 19,486 patients with IBD were tracked between May 2004 and June 2005. In an age- and sex-matched case-control study, eight patients developed anal canal cancer, and 14 developed rectal cancer. In a subgroup of 2,911 patients with past or present anorectal lesions, two developed anal squamous cell carcinoma, three developed fistula-associated cancer, and six developed rectal cancer. The incidence rates were 0.26 per 1,000 person-years for anal squamous cell carcinoma, 0.38 per 1,000 for fistula-associated cancer, and 0.77 per 1,000 for rectal cancer. In contrast, in 16,575 patients without anorectal lesions, the incidence of anal canal cancer was 0.08 per 1,000 patient-years, and rectal cancer incidence was 0.21 per 1,000 patient-years. Univariate analysis showed that the presence of anorectal lesions at cohort entry was the only factor significantly associated with anorectal cancer (OR 11.2, 95% CI: 1.18-551.51, p = 0.03). These results suggest that patients with CD with anorectal lesions are at higher risk for anorectal and rectal cancers compared to those without anorectal lesions or patients with UC.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>19223</offset><text>CQ3: What are the clinical and pathological features of IBD-associated GI neoplasia, and are there differences between Japanese and Western populations?</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>19376</offset><text>Statement</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_4</infon><offset>19386</offset><text>UC-associated colorectal neoplasia</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>19421</offset><text>It is presumed that there is no significant difference in the clinical and pathological features of UC-associated colorectal neoplasia between Japanese and Western populations. (Evidence level D)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_4</infon><offset>19617</offset><text>CD-associated GI neoplasia</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>19644</offset><text>There are regional or racial differences in the site of cancer development and histological types in CD-associated GI neoplasia. In Asia, anorectal cancer predominates, with a higher frequency of mucinous carcinoma. (Evidence level C)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>19879</offset><text>Comments</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>19888</offset><text>There are few reports on regional or racial differences in IBD-associated GI neoplasia. However, reports on cancer risk and genetic mutations sometimes show differing results, suggesting that some differences may exist. The explanation is provided below, divided by disease.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_4</infon><offset>20163</offset><text>UC-associated colorectal neoplasia</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>20198</offset><text>It has been reported that the frequency of mucinous carcinoma and signet ring cell carcinoma is higher in UC-associated colorectal cancer than in sporadic colorectal cancer. However, no reports have indicated histological differences between Western and Japanese populations. Additionally, genetic mutations such as p53, APC, and KRAS have been reported to show differences in expression between UC-associated colorectal cancer and sporadic colorectal cancer, but again, there are no reports of regional or racial differences.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>20725</offset><text>In Western reports, the co-occurrence of PSC has been listed as a risk factor for carcinogenesis. However, since the frequency of PSC is low in Japan, while there may be differences in the mechanisms of carcinogenesis, this is not clearly established. The recommendations for surveillance colonoscopy in UC do not significantly differ between Japan and Western countries. Given the common finding that cancers or dysplasia are more frequent in the left side of the colon, it is likely that UC-associated colorectal cancer in clinical and pathological terms is similar between Japan and Western countries.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_4</infon><offset>21330</offset><text>CD-associated GI neoplasia</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>21357</offset><text>Regarding CD-associated GI neoplasia, a systematic review and meta-analysis was conducted in 2021 based on case reports, case series, and cohort studies published to date. Both small bowel and colorectal cancers have been shown to have a high standardized incidence rate in CD-associated GI neoplasia. However, the prevalence is not as high, with colorectal cancer occurring in 57 of 7,344 cases (0.77%), and small bowel cancer in 17 of 7,344 cases (0.23%), indicating a higher risk but not particularly a high prevalence for small bowel cancer.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>21903</offset><text>There may be regional or racial differences in the location of colorectal cancer in CD. A review of three cohort studies from Western countries (total of 103 colorectal cancer cases) showed that 36.9% had right-sided colon cancer and 63.1% had left-sided colon cancer, with a higher frequency of left-sided colon cancer compared to sporadic colorectal cancer. However, in 17 reports from Asia, comprising a total of 107 cases, 15.9% had right-sided colon cancer, and 84.1% had left-sided colon cancer, with a predominant presence of anorectal cancer.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>22454</offset><text>In total, 54 papers reporting 208 cases of CD-associated anorectal cancer were reviewed. There were few descriptions regarding race or region, making detailed analysis impossible. The histological types included 49 cases of squamous cell carcinoma, 125 cases of adenocarcinoma (including mucinous carcinoma), and 34 other cases. Of the 49 cases of squamous cell carcinoma, 98% (48/49) were reported from Western countries. In contrast, in 64 cases from Asia, only one was squamous cell carcinoma, with the remaining majority being adenocarcinoma, including mucinous carcinoma.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>23031</offset><text>As mentioned, there may be regional or racial differences in the site and histological type of cancer development, but there is little information available from the reported cases. Moreover, since this review is based solely on English language reports and not all cases are accounted for, it is difficult to make definitive statements about these differences with clear evidence.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>23413</offset><text>CQ4: Does drug therapy for IBD affect the risk of developing GI neoplasia?</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>23488</offset><text>Statement</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>23498</offset><text>1. The oral administration of 5-aminosalicylic acid (5-ASA) preparations at a dosage of ≥1.2 g/day reduces the risk of UC-associated colorectal cancer. (Evidence level B)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>23671</offset><text>2. The administration of thiopurine preparations may reduce the risk of developing IBD-associated GI neoplasia, especially UC-associated colorectal cancer. (Evidence level C)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>23846</offset><text>Comments</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>23855</offset><text>No reports have been found regarding drug therapies that increase the risk of developing IBD-associated GI neoplasia. Although thiopurine preparations are known to be risk factors for lymphoma and non-melanoma skin cancer, no reports have indicated an increased risk of GI neoplasia associated with these medications. Therefore, in this CQ, the preventive effects of IBD treatment drugs on GI neoplasia development will be discussed.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>24289</offset><text>5-ASA preparations</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>24308</offset><text>There are many reports suggesting that the oral administration of 5-ASA preparations has a preventive effect on the development of UC-associated colorectal cancer. In a systematic review by Lyakhovich and Gasche, several mechanisms for chemical cancer prevention have been proposed, including interference with cell cycle progression, elimination of reactive oxygen species or nitrogen-derived metabolites, interference with cytokine signaling, and involvement in Wnt/beta-catenin signaling. In a meta-analysis conducted by O'Connor et al., the use of 5-ASA preparations at a dosage of ≥1.2 g/day was associated with a reduced risk of colorectal cancer (OR 0.5, 95% CI 0.3-0.9, p = 0.02) in patients with IBD. However, sulfasalazine did not show this effect. In a meta-analysis conducted by Qiu et al., similarly, 5-ASA preparations at a dosage of ≥1.2 g/day reduced the incidence of colorectal cancer in patients with IBD, but did not suppress the incidence of dysplasia. The chemopreventive effect was more pronounced in UC than in patients with CD. Bonovas et al.'s meta-analysis also showed a dose-dependent preventive effect on colorectal cancer and dysplasia with 5-ASA preparations compared to sulfasalazine, with a higher effect in UC than in patients with CD. Other meta-analyses have also shown the chemopreventive effect of 5-ASA preparations in UC-associated colorectal cancer. However, data regarding the discontinuation of 5-ASA preparations in patients in remission when combined with biological agents, specifically concerning colorectal cancer prevention, is limited.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>25897</offset><text>Sulfasalazine</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>25911</offset><text>In sulfasalazine, multiple meta-analyses have concluded that it does not play a role in the prevention of IBD-associated GI neoplasia. Therefore, the use of sulfasalazine for the prevention of IBD-associated GI neoplasia, whether in UC or CD, is strongly not recommended.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>26183</offset><text>Thiopurine preparations</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>26207</offset><text>There have been four meta-analyses investigating the preventive effect of thiopurine preparations on IBD-associated GI neoplasia. Three of these reports showed a preventive effect on UC-associated colorectal cancer. However, in cases of extensive colitis or PSC co-occurrence, no preventive effect was observed. There is heterogeneity in the studies. One report examined the difference in preventive effects between UC and CD, showing a significant preventive effect in UC (OR 0.67, 95% CI 0.45-0.98, p = 0.006) but no significant effect in CD (OR 1.06, 95% CI 0.54-2.09, p = 0.535). While there are reports supporting the preventive effect for UC alone, no such support has been found for CD. As no randomized controlled trials were included in all the meta-analyses, the Evidence level is considered C.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>27012</offset><text>Ursodeoxycholic acid</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>27033</offset><text>Ursodeoxycholic acid (UDCA) is commonly used to treat PSC, which is known to increase the risk of IBD-associated GI cancer. In a placebo-controlled randomized trial, UDCA administration in patients with UC with PSC was reported to have a preventive effect on colorectal cancer. However, there are reports suggesting that high-dose UDCA (28-30 mg/kg/day) increases the incidence of UC-associated colorectal neoplasia compared to placebo. Subsequent meta-analyses have not demonstrated a relationship between UDCA administration and the development of colorectal neoplasia (RR 0.87, 95% CI 0.51-1.49, p = 0.62). There is also insufficient evidence regarding the use of low-dose UDCA, and therefore, the use of UDCA for preventing IBD-associated GI neoplasia is not recommended.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>27809</offset><text>Biological agents</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>27827</offset><text>There have been no reports indicating that anti-tumor necrosis factor (TNF)-α antibodies prevent the development of GI neoplasia. Given the increasing number of new therapeutic agents, future accumulation of evidence is needed.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>28059</offset><text>Other medications</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>28077</offset><text>Aspirin has been reported to be associated with the prevention of sporadic colorectal cancer unrelated to genetic factors or IBD. A meta-analysis of non-steroidal anti-inflammatory drugs (NSAIDs) and aspirin regarding IBD-associated GI cancer prevention found high heterogeneity between studies (I2 &gt;50%), with insufficient high-quality evidence. Based on the available evidence, no significant preventive effect on GI neoplasia development was observed.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>28532</offset><text>Studies investigating the preventive effects of statins and folic acid on GI neoplasia found that statins did not reduce the risk of GI neoplasia (RR 0.98, 95% CI 0.43-2.25, p = 0.96). For folic acid, only a single retrospective cohort study was available, and evidence is still lacking.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>28820</offset><text>In summary, the administration of 5-ASA and thiopurine preparations has shown a preventive effect on IBD-associated GI neoplasia, especially in patients with UC. However, it remains unclear whether these effects are attributable to the drugs themselves or to the reduction of disease severity.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>29114</offset><text>CQ5: Is endoscopic surveillance effective for IBD-associated GI neoplasia?</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>29189</offset><text>Statement</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>29199</offset><text>Surveillance colonoscopy is strongly recommended in patients with IBD, as it may improve prognosis by enabling early detection of IBD-associated GI neoplasia, particularly colorectal cancer. (Recommendation grade: 1; Level of Evidence: C; Agreement Rate: 86%)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>29459</offset><text>Comments</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>29468</offset><text>In patients with IBD, the significance of surveillance colonoscopy has been emphasized. Although no randomized controlled trials have demonstrated a reduction in the incidence or mortality of colorectal cancer through surveillance colonoscopy, multiple cohort and case-control studies have shown that early detection of colorectal cancer is more achievable with surveillance. These studies also report better cancer-related prognosis and favorable cost-effectiveness associated with surveillance colonoscopy.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>29977</offset><text>Lutgens et al. conducted a retrospective cohort study and reported that among patients with IBD, the proportion of colorectal cancers detected at stage 0 or I (based on tumor-node-metastasis [TNM] classification) was 52% in the surveillance group versus 24% in the non-surveillance group (p = 0.004). Furthermore, the 5-year survival rate after colorectal cancer diagnosis was 100% in the surveillance group and 74% in the non-surveillance group (p = 0.042). These findings suggest that surveillance colonoscopy contributes to the more frequently detected colorectal cancers at an earlier stage and significantly lower colorectal cancer-related mortality.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>30633</offset><text>According to a Cochrane review, endoscopic surveillance in IBD may lead to a survival benefit by enabling early detection of colorectal cancer and dysplasia. In pooled analysis, early-stage cancer detection was significantly higher in the surveillance group compared to the non-surveillance group (16% vs. 8%; OR: 5.40, 95% CI: 1.51-19.30, p = 0.009), and the mortality rate was significantly lower (8% vs. 22%; OR: 0.36, 95% CI: 0.19-0.69, p = 0.002).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>31086</offset><text>In summary, although the level of evidence is low, surveillance colonoscopy for IBD-associated neoplasia is expected to improve colorectal cancer-related outcomes.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>31250</offset><text>CQ6: What is the optimal endoscopic method for surveillance in IBD-associated GI neoplasia (including initiation timing, surveillance intervals, and observation techniques)?</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>31424</offset><text>Statement</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>31434</offset><text>1. In patients with UC, surveillance colonoscopy is recommended beginning 8 years after disease onset. However, in patients with concomitant PSC, surveillance should begin at the time of diagnosis. (Recommendation grade: 2; Evidence level: C; Agreement rate: 71%)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>31698</offset><text>2. In patients with left-sided colitis, lesions involving more than one-third of the colon, or extensive colitis-type UC, surveillance colonoscopy is recommended every 1-2 years. For patients with concomitant PSC, annual surveillance is recommended. (Recommendation grade: 2; Evidence level: C; Agreement rate: 93%)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>32014</offset><text>3. For surveillance colonoscopy in UC, chromoendoscopy using dyes such as indigo carmine is recommended. (Recommendation grade: 2; Evidence level: B; Agreement rates: Grade 1 - 52%, Grade 2 - 48%)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>32211</offset><text>Comments</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>32220</offset><text>Although no randomized controlled trials or systematic reviews clearly define the optimal timing to initiate surveillance, several studies have reported surveillance colonoscopy in patients with IBD with a disease duration of at least 8 years. Based on this, surveillance colonoscopy is considered desirable once the disease has persisted for ≥8 years. However, cases of UC-associated CRC occurring within 8 years have been reported, necessitating caution.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>32679</offset><text>In the presence of active inflammation, both endoscopic and pathological detection of tumors may be difficult. Therefore, surveillance should ideally be performed during remission. Additionally, in patients with chronically persistent UC, there is a potential for increased CRC risk, and endoscopy should be conducted with this in mind.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>33016</offset><text>PSC in patients with UC is known to be a risk factor for CRC, and initiating surveillance at diagnosis is recommended in such cases. However, PSC is relatively rare in Japan, and it remains unclear whether the risk of CRC in Japanese patients with UC and PSC matches that of Western populations. Therefore, whether annual surveillance recommended abroad can be directly applied in Japan remains debatable.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>33422</offset><text>Surveillance intervals reported in studies vary from 1 to 3 years. A recent retrospective cohort study involving 77,824 patients with IBD suggested that colonoscopy within 1 year or between 1-3 years was associated with a reduced risk of CRC being diagnosed at an advanced stage compared to no surveillance (adjusted ORs: 0.40 [95% CI: 0.20-0.82] and 0.56 [95% CI: 0.32-0.98], respectively). Moreover, patients with PSC―due to their high cancer risk―should undergo annual surveillance. Some reports suggest that surveillance intervals should be tailored according to individual risk profiles. For example, patients with distal colitis may follow general population surveillance protocols.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>34115</offset><text>High-resolution colonoscopy with dye-based chromoendoscopy has been reported to reduce both CRC incidence and mortality in patients with IBD. One study reported that targeted biopsies using dye-based chromoendoscopy significantly improved the detection rate of non-polypoid dysplasia compared to white-light endoscopy. For patients with a history of neoplasia, concomitant PSC, or those with adenomas, random biopsies with chromoendoscopy are also considered.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>34575</offset><text>Recent studies comparing dye-based chromoendoscopy and narrow band imaging (NBI) showed no significant difference in dysplasia detection rates. Given the shorter procedure time and ease of use with NBI, its application in surveillance is expected to increase.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>34835</offset><text>CQ7: Are surveillance methods other than endoscopy effective for IBD-associated GI neoplasia?</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>34929</offset><text>Statement</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>34939</offset><text>At present, no effective modalities of surveillance other than colonoscopy have been established for IBD-associated GI neoplasia. (No Recommendation grade; Evidence level C) For surveillance of anorectal cancer, see CQ9.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>35160</offset><text>Comments</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>35169</offset><text>Colonoscopy is the recommended modalities of surveillance for IBD-associated GI neoplasia, and currently, there is no clear evidence supporting the efficacy of alternative modalities. Potential non-endoscopic surveillance includes tumor markers (such as carcinoembryonic antigen [CEA] and CA19-9), biomarkers like p53, and imaging techniques such as pelvic computed tomography (CT) or magnetic resonance imaging (MRI); however, existing reports are limited to case series involving rectal lesions in patients with CD. A retrospective study has also examined the use of positron emission tomography (PET) for surveillance in CD, but its utility was reported to be limited. Moreover, with imaging modalities such as CT, considerations must be made regarding the risks of radiation exposure and the financial burden on patients. Thus, any such examinations should be evaluated in terms of cost-benefit balance.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>36077</offset><text>Other exploratory studies have investigated risk stratification using detection of mutations in fecal DNA, and fecal calprotectin levels. Additionally, patient education using leaflets and videos has been suggested as potentially helpful, but these approaches remain in the exploratory research phase.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>36379</offset><text>CQ8: What is the optimal biopsy method for surveillance colonoscopy in patients with IBD?</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>36469</offset><text>Statement</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>36479</offset><text>1. For surveillance colonoscopy in patients with UC-associated colorectal neoplasia, targeted biopsies based on detailed endoscopic observation using chromoendoscopy or similar techniques are recommended. (Recommendation grade 2, Evidence level B; Agreement rate: Grade 1 - 59%, Grade 2 - 37%)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>36773</offset><text>2. For surveillance colonoscopy in UC-associated colorectal neoplasia, the implementation and method of random biopsies should be considered based on the patient's clinical history, endoscopic findings, and the endoscopist's skill. (No recommendation grade, Evidence level B)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>37049</offset><text>3. The significance and methodology of surveillance colonoscopy in CD remain unestablished, and accordingly, biopsy techniques are also not yet standardized. (No recommendation grade, Evidence level C)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>37251</offset><text>Comments</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>37260</offset><text>A non-inferiority randomized controlled trial (RCT) conducted in Japan using white-light endoscopy demonstrated that targeted biopsies had a comparable detection rate for neoplastic lesions to that of random biopsies during UC surveillance colonoscopy. This study included patients with total or left-sided colitis with a disease duration &gt;7 years. In the targeted biopsy group, biopsies were taken from lesions suspected of being neoplastic, with one additional random biopsy from the lower rectum. The random biopsy group underwent four biopsies every 10 cm throughout the colon, and additional targeted biopsies were taken as needed. Chromoendoscopy (including high magnification) was used at the endoscopist's discretion.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>37986</offset><text>However, dysplasia that is difficult to detect endoscopically may exist and can only be discovered through random biopsies. A prospective observational study using panchromoendoscopy with indigo carmine in 1,000 consecutive IBD cases (both UC and CD) reported a 15% increase in dysplasia detection by random biopsies. This study also included random biopsies of the background mucosa surrounding visible suspicious lesions, noting the effectiveness of random biopsies, particularly in patients with features such as a lead pipe appearance, PSC, or a history of dysplasia.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>38558</offset><text>Globally, the standard protocol for random biopsies in surveillance colonoscopy includes obtaining four biopsies every 10 cm throughout the colon. However, due to the prolonged procedure time and the burden on pathologists to examine numerous specimens, this approach is not always feasible in routine clinical practice.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>38879</offset><text>Given that UC-associated colorectal neoplasia frequently arises in the rectum and sigmoid colon, some institutions perform targeted biopsies of suspicious lesions based on changes in color or mucosal pattern, along with random biopsies specifically from these high-risk areas. Random biopsy techniques include random sampling within the colonic mucosa of inflamed segments defined by the extent of UC and random sampling of background mucosa around endoscopically visible lesions suspicious for neoplasia.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>39385</offset><text>Previous studies support the latter approach, while the former remains without standardized protocols regarding the extent of the colon to be biopsied or the number of biopsies to be taken. Currently, the biopsy method is determined based on the patient's history, endoscopic findings, and the endoscopist's experience.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>39705</offset><text>Hata et al. further evaluated the long-term effectiveness of targeted biopsies using follow-up data from patients with UC of more than 8 years' duration who participated in the aforementioned RCT. Their results showed a low incidence of CRC in patients with UC without dysplasia at baseline colonoscopy, supporting the use of targeted biopsies for surveillance.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>40067</offset><text>In contrast, since the incidence of CRC in patients with CD is significantly higher than that of the general population, European guidelines recommend surveillance colonoscopy for CD as well. However, in Japan, CD-associated colorectal neoplasia is predominantly located in the anorectal region, and thus, optimal methods for surveillance colonoscopy and biopsy in CD have not yet been established.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>40466</offset><text>CQ9: Is examination under anesthesia (EUA) recommended for the diagnosis of CD-associated anorectal cancer?</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>40574</offset><text>Statement</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>40584</offset><text>We weakly recommend performing EUA for the diagnosis of CD-associated anorectal cancer. (Recommendation Grade: 2, Evidence Level: D; Agreement rate: 89%)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>40738</offset><text>Comments</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>40747</offset><text>In Japan, CD-associated colorectal cancers are more commonly located in the distal colon compared to Western countries, with anorectal cancer accounting for approximately 80% of such cases. In UC, where cancer surveillance via endoscopy is well-established, early diagnosis has led to improved prognoses. However, in CD, the presence of fistulas and strictures often makes endoscopic examination difficult. While imaging modalities such as CT and MRI are useful for staging, they are limited in detecting early-stage cancers. Similarly, fluorodeoxyglucose positron emission tomography (FDG-PET) is not particularly useful for early detection due to the difficulty in distinguishing inflammation from malignancy and the low uptake in mucinous carcinomas, which are common in CD.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>41525</offset><text>Although there are reports of fistula-associated anal carcinoma with CD being detected via elevated carcinoembryonic antigen (CEA) levels, such cases often involve advanced cancers. Thus, tumor markers may aid in diagnosis but have limited value in early detection. Currently, no effective surveillance method exists for CD-associated CRC, and its prognosis remains poor.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>41897</offset><text>EUA has been reported to be useful for anorectal evaluation in CD, and is similarly considered beneficial for the diagnosis and differential diagnosis of associated anorectal cancer.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>42080</offset><text>EUA is typically performed under spinal, epidural, or general anesthesia, with the patient positioned in the lithotomy or jack-knife position. The examination extends beyond the anal verge to include the perineum, buttocks, and sacral area to ensure a broad and clear visual field. During EUA, biopsy specimens are taken from fistula tracts, ulcerative lesions, and skin tags around the anus. For diagnosing anorectal cancer, random biopsies of the anorectal mucosa, cytological evaluation of lavage fluid from the anal canal and fistulous tracts, and other tissue sampling techniques are used.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>42675</offset><text>In cases where endoscopic observation is difficult due to anal stenosis and pain, combining EUA with colonoscopy can allow examination up to the upper rectum.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>42834</offset><text>Risk factors for CD-associated anorectal cancer include long disease duration. One report targeting patients with CD with a disease duration &gt;10 years found a cancer detection rate of 15.5% using EUA. The average age at cancer diagnosis was younger than that typically seen in sporadic colorectal cancers, with an average disease duration &gt;20 years from CD onset to cancer diagnosis.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>43218</offset><text>In that study, the utility of EUA-based biopsies for surveillance was assessed by excluding cases with obvious cancer symptoms or visibly advanced disease. Among the remaining cases, the cancer detection rate was 4.9%, with all detected cancers being Stage II; there were no Stage III or higher cases. These results suggest that EUA with biopsy may facilitate earlier cancer detection in asymptomatic patients.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>43629</offset><text>EUA enables examination in an optimal position with pain eliminated and allows for transanal tissue sampling. Therefore, EUA is recommended for the diagnosis of CD-associated anorectal cancer.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>43822</offset><text>CQ10: What endoscopic findings support to differentiate between UC-associated colorectal neoplasia and (non-UC-associated) sporadic colorectal neoplasia?</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>43976</offset><text>Statement</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>43986</offset><text>1. To differentiate between UC-associated colorectal neoplasia and (non-UC-associated) sporadic colorectal neoplasia endoscopically, a comprehensive endoscopic assessment should be performed based on the extent of UC inflammation, background mucosal findings, shape, surface structure, margins, and the presence of surrounding flat dysplastic lesions. (Evidence Level: C)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>44358</offset><text>2. Endoscopic differential diagnosis between UC-associated and (non-UC-associated) sporadic colorectal neoplasia has not been established, a comprehensive approach according to not only endoscopic findings but also clinical evaluation and pathological findings should be performed. (Evidence Level: C)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>44660</offset><text>Comments</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>44669</offset><text>Differential diagnosis between UC-associated colorectal neoplasia (UCAN) and (non-UC-associated) sporadic colorectal neoplasia is essential because of difference for not only the pathogenetic development but treatment strategy. The Kudo-Tsuruta and the Japan NBI Expert Team (JNET) classifications were developed for sporadic lesions based on the collation between magnified endoscopic findings and pathologic findings in Japan, and have not been established for UCAN according to a similar approach, although previous published papers used the Kudo-Tsuruta and JNET classifications. Villous surface patterns and elongated or irregular crypts of magnifying chromoendoscopic findings can be observed in regenerative or non-neoplastic remission mucosa, necessitating cautious interpretation. Endoscopic differentiation is performed as a comprehensive evaluation based on endoscopic findings, including the background mucosa. Lesions located outside the extension of previous UC inflammation are typically considered sporadic lesions. Similarly, neoplastic lesions located in areas other than the sigmoid colon or rectum―common sites for UCAN―tend to suggest sporadic neoplasia. In contrast, endoscopic finding to suggest prior severe inflammation, for instance scarring, supports a UCAN.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>45959</offset><text>Attempts have been made to differentiate the lesions according to endoscopic findings of neoplasia itself. The Japanese experts' consensus recommends diagnosing UCAN comprehensively based on shape, color, margins, surface structure, and vascular architecture. However, even the authors recommended that when four specific findings―non-polypoid lesion, irregular vessel architecture, irregular surface pattern, and the presence of ulceration within the lesion―were used, the diagnostic accuracy was limited (accuracy 71%, sensitivity 65%, specificity 81%, positive predictive value [PV] 86%, negative PV 57%). Limitation of endoscopic differential diagnosis still remains between UCAN and sporadic neoplasia.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>46671</offset><text>The Surveillance for Colorectal Endoscopic Neoplasia Detection and Management in Inflammatory Bowel Disease Patients: International Consensus Recommendations (SCENIC) recommend to perform the endoscopic diagnosis, including additional information, such as the presence of ulcer, and the margin of visible lesion. However, the frequency of ulceration in the colonic mucosa should decrease in the era of the treat-to-target strategy for endoscopic remission. Endoscopic features that are considered highly specific for UCAN, such as a pinecone-like or villous appearance, have been reported with a specificity of 96.8%, but their lower sensitivity should be recognized (21.4%). It is also important to consider the possible presence of invisible flat dysplasia surrounding visible lesions, which will be difficult to detect endoscopically, and require careful endoscopic observation and taking biopsy (Figure 1).</text></passage><passage><infon key="file">2432-3853-10-1-0135-g001.jpg</infon><infon key="id">g001</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>47582</offset><text>Endoscopic Diagnosis of UC-associated Colorectal Neoplasia.</text></passage><passage><infon key="file">2432-3853-10-1-0135-g001.jpg</infon><infon key="id">g001</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>47642</offset><text>A comprehensive assessment of shape, color, margins, surface structure, and vascular architecture should be performed to differentiate between neoplastic and non-neoplastic lesions, or UC-associated colorectal neoplasia (UCAN) and (non-UC-associated) sporadic colorectal neoplasia.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>47924</offset><text>In clinical practice, detailed precise evaluation using chromoendoscopy with magnification to perform the endoscopic differential diagnosis, future's issue, is essential, although even histopathological assessment may not always distinguish between UCAN and sporadic neoplasia definitively. Therefore, a comprehensive diagnostic approach that incorporates clinical history and endoscopic and pathological findings should be performed. Meanwhile, differentiating between UCAN and serrated lesions arising in UC endoscopically remains a future challenge.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>48477</offset><text>CQ11: What pathological diagnostic terminology, classification, and criteria should be used for IBD-associated GI neoplasia?</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>48602</offset><text>Statement</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>48612</offset><text>For the pathological diagnosis of IBD-associated GI neoplasia, the “Riddell system” and the “Diagnostic Criteria for Epithelial Dysplasia in Ulcerative Colitis” developed by the Japanese Inflammatory Bowel Disease Research Group under the Ministry of Health and Welfare (currently the Ministry of Health, Labour, and Welfare) are used.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>48956</offset><text>Comments</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>48965</offset><text>The most widely used international diagnostic criterion for intraepithelial neoplasia arising in IBD is the classification developed by Riddell et al. from the Dysplasia Morphology Study Group (DMSG), known as the Riddell system. However, differences exist between Western and Japanese perspectives, such as whether intramucosal carcinoma should be included under high-grade dysplasia (HGD). In addition, the Riddell system does not distinguish between IBD-associated mucosal neoplasia and sporadic adenomas/adenocarcinomas. To address these issues, Japan established its own diagnostic criteria in 1994 through the Ministry of Health and Welfare Study Group. Both the Riddell system and the Ministry of Health, Labour, and Welfare classification (MHLW classification) are applicable to biopsy and resected specimens.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>49783</offset><text>The Riddell system classifies histologically atypical epithelium in IBD-affected mucosa into three categories: negative for dysplasia, indefinite for dysplasia, and positive for dysplasia (Table 5). The “positive” category is further divided into low-grade dysplasia (LGD) and HGD based on the degree of atypia. UC-associated intramucosal neoplasia sometimes involves poorly differentiated adenocarcinomas de novo or coexisting with well- to moderately-differentiated adenocarcinomas. Classifying such lesions together with other HGD cases could lead to underestimation. Therefore, more accurate histologic diagnostic criteria reflecting malignancy potential are needed.</text></passage><passage><infon key="file">t005.xml</infon><infon key="id">t005</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>50458</offset><text>Riddell System.</text></passage><passage><infon key="file">t005.xml</infon><infon key="id">t005</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; style=&quot;border-top:solid thin;&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Negative for dysplasia&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Indefinite for dysplasia&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Positive for dysplasia&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Low-grade dysplasia (LGD)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; style=&quot;border-bottom:solid thin;&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;High-grade dysplasia (HGD)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>50474</offset><text>Negative for dysplasia	 	Indefinite for dysplasia	 	Positive for dysplasia	 	Low-grade dysplasia (LGD)	 	High-grade dysplasia (HGD)	 	</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>50609</offset><text>In contrast, since the Riddell system treats all mucosal neoplasia arising in IBD as IBD-associated dysplasia, sporadic adenomas/intramucosal adenocarcinomas are also diagnosed as IBD-associated dysplasia, potentially resulting in unnecessary colectomy.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>50863</offset><text>Considering these issues, the MHLW classification distinguishes neoplastic lesions that can be diagnosed as carcinoma (UC-IV), even if limited to the mucosa, from those that cannot be diagnosed as cancer (UC-III) (Table 6). In addition, lesions diagnosable as typical sporadic adenomas are categorized separately. This approach is based on the biological differences between IBD-associated dysplasia and sporadic adenomas even arising in IBD, and this information is important in providing appropriate therapeutic strategy in the future.</text></passage><passage><infon key="file">t006.xml</infon><infon key="id">t006</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>51401</offset><text>Diagnostic Criteria for Epithelial Dysplasia in Ulcerative Colitis by the Research Group for Intractable Inflammatory Bowel Disease of the Ministry of Health and Welfare, Japan (MHLW Classification).</text></passage><passage><infon key="file">t006.xml</infon><infon key="id">t006</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; style=&quot;border-top:solid thin;&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;UC‒I．Inflammatory lesion&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;UC‒II．Indefinite for neoplasia: difficult to distinguish between inflammatory and neoplastic lesion&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;UC‒IIa．Suggestive of inflammation&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;UC‒IIb．Suggestive of neoplasia&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;UC‒III．Neoplastic lesion that cannot be diagnosed as carcinoma&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;UC‒IV．Carcinoma&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>51601</offset><text>UC‒I．Inflammatory lesion	 	UC‒II．Indefinite for neoplasia: difficult to distinguish between inflammatory and neoplastic lesion	 	UC‒IIa．Suggestive of inflammation	 	UC‒IIb．Suggestive of neoplasia	 	UC‒III．Neoplastic lesion that cannot be diagnosed as carcinoma	 	UC‒IV．Carcinoma	 	</text></passage><passage><infon key="file">t006.xml</infon><infon key="id">t006</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>51907</offset><text>Notes:</text></passage><passage><infon key="file">t006.xml</infon><infon key="id">t006</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>51914</offset><text>1. This classification also incorporates the concept of “dysplasia” as defined by Riddell et al..</text></passage><passage><infon key="file">t006.xml</infon><infon key="id">t006</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>52016</offset><text>2. Lesions diagnosed as hyperplastic lesion should be described as such.</text></passage><passage><infon key="file">t006.xml</infon><infon key="id">t006</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>52089</offset><text>3. Lesions that cannot be distinguished from conventional adenomas should be described accordingly.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>52189</offset><text>While the Riddell system remains the global standard, due to its limitations, it is recommended that when this system is used, a supplementary diagnosis based on the MHLW classification be provided.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>52388</offset><text>CQ12: Is immunohistochemical staining (p53 and Ki-67) recommended in the biopsy-based pathological diagnosis of IBD-associated GI neoplasia?</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>52529</offset><text>Statement</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>52539</offset><text>The combined use of immunohistochemical staining for p53 and Ki-67 is recommended in the biopsy-based pathological diagnosis of IBD-associated GI neoplasia. (Recommendation grade: 2; Evidence level: D; Consensus rate: Grade 1: 57%, Grade 2: 43%)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>52785</offset><text>Comments</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>52794</offset><text>In the pathological diagnosis of biopsy specimens obtained during colonoscopy in patients with IBD, in addition to assessing disease activity, two key diagnostic goals are (1) detecting neoplastic lesions, and (2) distinguishing IBD-associated GI neoplasia from sporadic neoplasia.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>53076</offset><text>Regarding (1), diagnosis is generally straightforward in biopsy samples from invasive cancers with marked cytological and architectural atypia. However, pathological evaluation of early lesions, particularly mucosal non-invasive lesions classified as LGD or HGD (including non-invasive intramucosal carcinoma in Japan), can be difficult, especially in differentiating from non-neoplastic inflammatory atypia. Studies evaluating inter-observer diagnostic reproducibility among pathologists have shown relatively good agreement for HGD versus non-neoplastic lesions (kappa = 0.54-0.82), but lower reproducibility when including LGD (kappa = 0.25-0.30).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>53727</offset><text>For (2), characteristic histological features of IBD-associated GI neoplasia (see CQ13), along with endoscopic and clinical findings, are considered important. In particular, it can be difficult to distinguish IBD-associated GI neoplasia from sporadic tumors in localized raised lesions formerly termed “dysplasia-associated lesion or mass (DALM)”(see note).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>54090</offset><text>Given these challenges, immunohistochemical staining for p53 and Ki-67 is often used adjunctively when it is difficult to distinguish IBD-associated dysplasia from inflammatory atypia or from sporadic adenoma or carcinoma using hematoxylin and eosin (H&amp;E)-staining alone.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>54362</offset><text>TP53 gene alterations play a critical role in the development of IBD-associated GI neoplasia and, unlike in sporadic adenomas, occur early in tumorigenesis. A 2017 meta-analysis demonstrated a significantly higher frequency of TP53 mutations in IBD-associated CRC compared to sporadic cases. Similarly, immunohistochemical staining for p53 has been shown to be useful in UC-associated tumors, including invasive cancer and dysplasia. While p53 abnormalities can also be observed in sporadic intramucosal high-grade tumors, UC-associated non-invasive mucosal lesions often show a characteristic “unique basal pattern,” in which p53 positivity is confined to the deeper crypt bases. Evaluating the distribution of positive cells is helpful in distinguishing from sporadic tumors.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>55144</offset><text>It should be noted that staining patterns of p53 can vary depending on the monoclonal antibody used, and understanding the characteristics of each antibody is important. For example, DO-7 tends to show a higher frequency and stronger intensity of positive cells compared to PAb1801. Abnormal p53 staining reflecting TP53 mutations includes continuous strong nuclear positivity (suggestive of mutant protein accumulation) and complete negativity (suggestive of truncated protein or protein loss). In contrast, scattered weakly positive cells within the Ki-67 positive proliferative zone typically suggest wild-type TP53 and are interpreted as normal.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>55794</offset><text>Ki-67-positive cells in IBD-associated GI neoplasia are densely distributed in the deep mucosal layers of dysplastic crypts and decrease toward the surface, showing a “bottom-up” distribution. In LGD, positivity is confined to the lower half of the mucosa, whereas in HGD and carcinoma, Ki-67 positivity tends to extend to the upper half. In sporadic adenomas, Ki-67-positive cells are typically distributed predominantly in the superficial mucosa. Therefore, evaluating Ki-67 distribution is helpful in differentiating lesions formerly termed DALMs from sporadic adenomas.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>56372</offset><text>These findings suggest the utility of Ki-67 staining in determining IBD-associated GI neoplasia and distinguishing LGD from HGD. Thus, in the pathological evaluation of biopsy specimens obtained during endoscopic examinations of patients with IBD, the use of immunohistochemical staining for p53 and Ki-67, in addition to H&amp;E staining, appears beneficial. However, large-scale studies demonstrating superiority of combined immunostaining over H&amp;E alone are lacking, and further validation is necessary. Additionally, some reports indicate that abnormal p53 expression may be observed in crypt epithelium without clear morphological features of neoplasia on H&amp;E staining.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>57043</offset><text>At present, p53 and Ki-67 immunohistochemistry should be considered auxiliary tools used only when H&amp;E findings are inconclusive or differential diagnosis is challenging, with accurate histopathological evaluation of H&amp;E sections remaining the foundation of diagnosis.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>57312</offset><text>Note: The term “DALM” is no longer in use.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>57359</offset><text>CQ13: What are the pathological differences between IBD-associated GI neoplasia and sporadic neoplasia?</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>57463</offset><text>Statement</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_4</infon><offset>57473</offset><text>Carcinoma invading the submucosa or deeper layers (invasive carcinoma)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>57544</offset><text>Compared to sporadic neoplasia, IBD-associated invasive carcinomas show a higher frequency of histological subtypes such as mucinous adenocarcinoma, poorly differentiated adenocarcinoma, and signet ring cell carcinoma.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_4</infon><offset>57763</offset><text>Intramucosal neoplasia</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>57786</offset><text>IBD-associated GI neoplasia is characterized by features such as: intramucosal dedifferentiation, superficial cellular differentiation, cellular differentiation abnormalities, lack of increased glandular density, full-thickness replacement of the mucosa by neoplastic glands, straight glands with few branches, gradual transition to the surrounding non-neoplastic mucosa, flat gross morphology, bottom-up pattern of proliferative activity, and aberrant expression of p53 protein.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>58266</offset><text>Comments</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>58275</offset><text>Invasive carcinoma associated with IBD more frequently exhibits histological subtypes such as mucinous adenocarcinoma, poorly differentiated adenocarcinoma, and signet ring cell carcinoma compared to sporadic GI cancers. Previous studies have reported that approximately 40% of colorectal cancers associated with UC or CD fall into these histological subtypes. This trend is consistent across Japan and Western countries. However, in CD-associated CRC, Japan shows a higher frequency of anal canal cancers, particularly fistula-associated cancers, with one report indicating that 64.5% of these were histologically mucinous adenocarcinomas.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>58916</offset><text>There are no definitive histopathological criteria to clearly distinguish, on a case-by case basis, between IBD-associated carcinoma and sporadic carcinomas. Therefore, in practice, all invasive carcinomas arising in patients with IBD tend to be regarded as IBD-associated GI neoplasia. However, when an overt sporadic adenomatous lesion contiguous with the invasive component is clearly observed, the lesion is more likely to be a sporadic tumor.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>59364</offset><text>In contrast, IBD-associated intramucosal neoplasia often exhibits ≥1 of the following histological features, which are less commonly seen in sporadic intramucosal neoplasia:</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>59540</offset><text>1. Intramucosal dedifferentiation: Dedifferentiation of mucosal components in otherwise well- or moderately-differentiated adenocarcinoma to poorly differentiated features.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>59713</offset><text>2. Superficial cellular differentiation: Cellular atypia is most pronounced in the deeper parts of the mucosa, with cells showing differentiation toward mucin-rich cells as they migrate toward the surface.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>59919</offset><text>3. Abnormal cellular differentiation: This includes pancellular change, characterized by abundant endocrine or Paneth cells throughout the entire neoplastic gland; dystrophic goblet cells, which are goblet cells with loss of nuclear polarity; or basal cell proliferation, where small round hyperchromatic nuclei show almost no differentiation.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>60263</offset><text>4. Lack of increased glandular density, with replacement of the entire mucosal thickness by tumor glands.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>60369</offset><text>5. Neoplastic glands with minimal branching, forming relatively straight tubular structures.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>60462</offset><text>6. Gradual transition to surrounding non-neoplastic mucosa, without compressive or replacing growth patterns.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>60572</offset><text>7. Flat gross appearance.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>60598</offset><text>8. “Bottom-up” proliferative pattern on Ki-67 immunostaining, where Ki-67-positive cells are densely distributed in the mid-to-deep zones of the crypts and decrease toward the surface, similar to normal crypts (see CQ12).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>60824</offset><text>9. Abnormal p53 immunostaining, showing either diffuse and strong positive, or completely negative (see CQ12).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>60935</offset><text>If none of the above are observed, the lesion is diagnosed as a sporadic tumor. While Ki-67 and p53 immunostaining are useful adjuncts for distinguishing between IBD-associated and sporadic intramucosal neoplasia, it is essential to note the following caveats: in IBD-associated neoplasia with marked atypia, Ki-67 positivity may become diffusely distributed. In sporadic neoplastic lesions diagnosed as carcinoma, p53 abnormal expression may also be observed.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>61396</offset><text>CQ14: Is total colectomy recommended for UC-associated colorectal neoplasia?</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>61473</offset><text>Statement</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>61483</offset><text>1. Total proctocolectomy is strongly recommended for HGD and resectable colorectal cancer. (Recommendation grade: 1, Evidence level: C, Consensus rate: 93%)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>61640</offset><text>2. Total proctocolectomy is weakly recommended for LGD, particularly when the risk of coexisting cancer is considered high. (Recommendation grade: 2, Evidence level: C, Consensus rate: 93%)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>61830</offset><text>3. However, depending on tumor characteristics, endoscopic resection may also be considered (see CQ21).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>61934</offset><text>Comments</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>61943</offset><text>There are no randomized controlled trials comparing the efficacy of total proctocolectomy to other treatment options for UC-associated colorectal neoplasia. UC-associated neoplasia often presents as multifocal disease, both synchronously and metachronously, and these lesions are not always readily identifiable by endoscopy. When managing UC-associated neoplasia, it is crucial to consider not only the treatment of the visible lesion at the time of diagnosis but also the risk of synchronous or future colorectal neoplasia elsewhere in the colon and the rectum, along with the patient's overall condition.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>62551</offset><text>The incidence of synchronous multiple carcinomas in UC-associated CRC is reported to be 12%-30%, which is significantly higher than the 2%-3% seen in sporadic CRC. A multicenter study from Japan reported a 16% rate of synchronous invasive carcinomas among 406 surgical cases.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>62827</offset><text>For dysplasia, a review of 10 prospective studies showed that CRC was found in colectomy specimens in 19% of LGD and 42% of HGD cases when colectomy was performed immediately after diagnosis. If surgery was delayed and preceded by a period of surveillance, cancer was found in 8% of LGD and 32% of HGD cases. This indicates a high frequency of coexisting or subsequent cancer, especially in HGD.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>63223</offset><text>Therefore, total proctocolectomy is recommended for patients with UC who are diagnosed with HGD or resectable CRC, considering the potential for synchronous lesions and future cancer risk. Even in cases of LGD, total proctocolectomy should be considered if there is a strong suspicion of coexisting HGD or invasive cancer.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>63546</offset><text>Surgical options other than total proctocolectomy include subtotal colectomy with rectal preservation and ileorectal anastomosis (IRA). However, studies have shown that the risk of developing cancer in the retained rectum post-IRA is 3.2% at 10 years and 7.3% at 20 years, while dysplasia occurs at rates of 7.1% at 10 years and 14% at 20 years. The risk is significantly higher compared to total proctocolectomy (OR: 6.4, 95% CI: 4.3-9.5). The standardized incidence ratio (SIR) for rectal cancer is 8.7 after IRA, and 3.8 in the retained rectum after subtotal colectomy, compared to 0.4 after total proctocolectomy with ileal pouch-anal anastomosis.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>64198</offset><text>Thus, total proctocolectomy remains the standard surgical approach for resectable UC-associated neoplasia, and partial colectomy is generally not recommended, except in special circumstances.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>64390</offset><text>However, the choice of surgical procedure should not be based solely on curability but must also consider surgical tolerance, activities of daily living (ADL), anal sphincter function, and factors such as whether the tumor is IBD-associated or sporadic (see CQ1, CQ10, CQ12), degree of dysplasia (LGD, HGD, carcinoma), tumor location (colon vs. rectum, solitary vs. multiple), and cancer risk factors (disease duration, extent of disease, PSC, family history of CRC; see CQ2).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>64867</offset><text>In certain special cases, such as elderly patients, those with serious comorbidities, impaired anorectal function, or advanced-stage cancer, other options such as partial colectomy, subtotal colectomy, IRA, or permanent ileostomy after total proctocolectomy may be considered. For lesions near the rectum, partial resection, such as low anterior resection, may compromise future sphincter-preserving options and is therefore not recommended.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>65309</offset><text>In patients with LGD, especially those at high surgical risk, more conservative strategies may be considered, including limited resection (e.g., total or subtotal colectomy, segmental resection; see CQ15) combined with intensive endoscopic surveillance, or even no resection with close endoscopic surveillance.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>65620</offset><text>Recent advancements in endoscopic imaging techniques, such as chromoendoscopy and high-definition endoscopy, have improved the detection of IBD-associated neoplasia. In cases of LGD, when feasible, endoscopic resection followed by strict surveillance has emerged as a viable strategy (see CQ21). However, if HGD or carcinoma is found in the resected specimen, total proctocolectomy is recommended due to the risk of synchronous lesions and future cancer development.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>66087</offset><text>CQ15: Is segmental colectomy recommended for CD-associated colorectal neoplasia?</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>66168</offset><text>Statement</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>66178</offset><text>Surgical treatment for resectable colorectal neoplasia in patients with CD generally follows the principles applied to sporadic CRC, and segmental colectomy with regional lymph node dissection is often performed. However, there is insufficient evidence comparing segmental colectomy to more extensive surgeries such as total colectomy, and thus the clinical significance remains unclear. (Recommendation grade: None; Evidence Level: D)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>66614</offset><text>Comments</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>66623</offset><text>It is often difficult to diagnose CD-associated colorectal tumors preoperatively. When deciding on treatment, one must consider the patient's nutritional status, presence of other surgical indications apart from the tumor, treatment for tumor lesions confirmed at diagnosis, the possibility of synchronous multifocal lesions in other parts of the colon, and the risk of developing metachronous colorectal neoplasia.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>67039</offset><text>Currently, knowledge on CD-associated colorectal neoplasia is limited compared to that of UC-associated neoplasia. It is believed that the carcinogenesis pathway involving dysplasia arising from inflammation is similar in both CD and UC-associated colorectal neoplasia. Surgical procedures typically include abdominoperineal resection or segmental colectomy with regional lymph node dissection, as is done for sporadic CRC. However, CD-associated colorectal neoplasia are reported to have a high frequency of both synchronous and metachronous multifocal lesions. According to a report from Western countries, among patients who underwent total or subtotal colectomy for dysplasia, HGD or carcinoma was diagnosed in 73% of cases, and multifocal lesions were detected in 44%. Another study reported that 40% of patients who underwent segmental or subtotal colectomy for CRC were later diagnosed with metachronous carcinoma. Furthermore, segmental colectomy is reported to have a significantly higher reoperation rate compared to total colectomy with permanent ileostomy (HR 5.76, 95% CI: 1.65-20.11, p = 0.006). However, clear criteria for selecting appropriate cases for segmental colectomy have not been established.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>68256</offset><text>In Japan, CD-associated colorectal neoplasia most commonly occur in the anal canal (51%) and rectum (29%), indicating a high frequency of anorectal cancer. The incidence of left-sided colon cancer is 84.1% in Asia compared to 63.1% in Western countries (p &lt; 0.01). Therefore, it is not feasible to directly apply Western data to Japanese patients. Given the current lack of accumulated evidence, the significance of segmental colectomy remains unclear.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>68709</offset><text>CQ16: Is hand-sewn ileal pouch-anal anastomosis (IPAA) recommended as a sphincter-preserving surgery for UC-associated colorectal neoplasia?</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>68850</offset><text>Statement</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>68860</offset><text>Weakly recommended to perform hand-sewn IPAA as a sphincter-preserving surgery for UC-associated colorectal neoplasia. (Recommendation grade: 2; Evidence Level: C; Agreement Rate: 97%)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>69045</offset><text>Comments</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>69054</offset><text>There are no RCTs comparing quality of life (QOL) or long-term outcomes between hand-sewn IPAA and stapled IPAA for UC-associated colorectal neoplasia. The selection of surgical procedure should take into account patient-related factors (such as tumor location, age, degree of obesity, etc.), and must be conducted with informed consent.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>69392</offset><text>As mentioned in CQ14, UC-associated colorectal neoplasia frequently involves synchronous multiple lesions. The key difference between hand-sewn IPAA and stapled IPAA is whether the mucosa of the anal transitional zone (ATZ) is preserved or removed. The frequency of dysplasia in the ATZ is reported to be 2.5%-4.4%, and the incidence of cancer in the ATZ of resected specimens from UC-associated colorectal neoplasia is reported at 6.4%.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>69830</offset><text>Some reports indicate that while no carcinoma was detected in the ATZ 10 years after stapled IPAA, dysplasia was found in 4.5% of patients, and those with cancer or dysplasia in preoperative endoscopy or resection specimens were at higher risk. However, increasing numbers of ATZ cancer cases after stapled IPAA have been reported, including 12 cases by 2017; of the 10 with known surgical indications, five were operated on for cancer or dysplasia. Based on these findings, hand-sewn IPAA is recommended for patients with UC-associated colorectal neoplasia.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>70389</offset><text>In contrast, there are reports of cancer development even after hand-sewn IPAA. Some hypothesize that the cancer arose from residual mucosa left in an island-like pattern in the anal canal, or from visible residual mucosa near the dentate line. However, many of these cancers developed within 3 years postoperatively, and it is speculated that these cases may represent local recurrence of preoperative rectal cancer or misdiagnosed cancer (rather than dysplasia) at the time of surgery.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>70877</offset><text>Therefore, even when hand-sewn IPAA is performed in patients with rectal cancer or dysplasia, postoperative surveillance of the anastomotic region, as done with stapled IPAA, is necessary.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>71066</offset><text>In cases with UC-associated neoplasia limited to the colon, factors such as age and obesity should also be considered when selecting surgical options. While some reports suggest no significant difference in postoperative sphincter function between hand-sewn IPAA and stapled IPAA, others favor stapled IPAA in this regard, and it should be presented as an alternative.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>71435</offset><text>As previously discussed, while hand-sewn IPAA is recommended for UC-associated colorectal neoplasia, anatomical and technical limitations must be considered. If intraoperatively the pouch cannot reach the anus, stapled IPAA with postoperative endoscopic surveillance of the ATZ should be considered. For cases with neoplasia in the rectum, refer to CQ17.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>71790</offset><text>CQ17: Is sphincter-preserving surgery recommended for UC-associated rectal cancer?</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>71873</offset><text>Statement</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>71883</offset><text>1. Sphincter-preserving surgery for UC-associated upper rectal cancer is weakly recommended. (Recommendation grade: 2; Evidence Level: C; Agreement Rate: Grade 1 - 69%, Grade 2 - 24%)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>72067</offset><text>2. For lower rectal cancer, sphincter-preserving surgery should be considered based on tumor location and stage, as well as patient preference. It should be performed only after thorough preoperative evaluation and obtaining informed consent. (Recommendation grade: None; Evidence Level: D)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>72358</offset><text>Comments</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>72367</offset><text>Sphincter-preserving procedures for UC-associated rectal cancer broadly include endoscopic resection, hand-sewn IPAA, and stapled IPAA, as alternatives to total colectomy with permanent ileostomy.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>72564</offset><text>Neoadjuvant chemoradiotherapy for advanced lower rectal cancer aiming for sphincter preservation has been reported in case studies but lacks sufficient evidence to support a recommendation (see CQ26).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>72765</offset><text>Endoscopic treatment for UC-associated colorectal neoplasia can be considered for diagnostic purposes (i.e., total biopsy). However, endoscopic submucosal dissection (ESD) in patients with UC shows that in 97% of cases, the submucosa is already fibrotic, making subsequent surgery technically challenging and potentially compromising sphincter function. Therefore, ESD is not recommended as a therapeutic option (see CQ21).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>73189</offset><text>Treatment of UC-associated upper rectal cancer may follow the same principles as colonic UC-associated neoplasia. For neoplasia in the upper rectum, hand-sewn IPAA is more strongly recommended than stapled IPAA (see CQ16). In patients where hand-sewn IPAA is anatomically difficult, stapled IPAA with postoperative endoscopic surveillance is a reasonable alternative.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>73557</offset><text>UC-associated rectal cancer poses unique challenges compared to sporadic rectal cancer, including indistinct borders between neoplasia and non-neoplasia tissue, and a higher risk of positive distal resection margins. The presence of peritumoral dysplasia also complicates surgical decision-making.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>73855</offset><text>Surgical choices generally include hand-sewn IPAA or total colectomy with permanent ileostomy. The final decision often depends on patient preference. Due to the limited number of cases and literature, with the largest series only reporting 41 cases, there is insufficient evidence to make a strong surgical recommendation.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>74179</offset><text>Although there are isolated reports of performing hand-sewn IPAA after neoadjuvant chemoradiotherapy or with intersphincteric resection (ISR) for UC-associated lower rectal cancer, these are limited to case reports and are not sufficient to justify a recommendation.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>74446</offset><text>In summary, there is insufficient evidence to recommend sphincter-preserving surgery for UC-associated lower rectal cancer. Surgical decisions must consider preoperative pathology, age, performance status, personal priorities, and must be made only after obtaining thorough informed consent.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>74738</offset><text>CQ18: What is the optimal surgical procedure for patients with CD-associated anorectal cancer?</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>74833</offset><text>There is no high-level evidence on surgical outcomes (including prognosis and complications) for CD-associated anorectal cancer. However, abdominoperineal resection (APR) is commonly performed in clinical practice. (Recommendation grade: None; Evidence Level: D)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>75096</offset><text>Explanation</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>75108</offset><text>The surgical approach for CD-associated anorectal cancer should generally follow principles similar to those for sporadic CRC, but must also take into account the specific characteristics of CD-associated GI cancer. Although high-level evidence from large-scale studies is lacking, Japanese reports offer useful insights.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>75430</offset><text>Many patients with CD present with anal lesions such as fistulas. Mucinous adenocarcinoma is frequently observed―50% in a Japanese series of 122 CD-associated GI cancer cases, and 30%-54% of anorectal cancer cases in other reviews.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>75664</offset><text>The depth of invasion is often advanced. One systematic review reported that 62% of CD-associated anorectal cancers were T3 or higher, and another Japanese study reported 91% invasion beyond the muscularis propria.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>75879</offset><text>Due to these characteristics, APR is the most commonly chosen procedure, and was performed in 67% of cases in a comprehensive report on CD-associated cancers (see CQ14). Additionally, in many cases―including cancer arising from fistulas―invasion into surrounding rectal tissue makes it difficult to achieve negative surgical margins, and residual cancer was found in 29% of cases (7 of 24 cases) in a single-institution study. For this reason, pelvic exenteration may be necessary in some cases to ensure margin-negative resection.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>76415</offset><text>Sphincter-preserving procedures, such as ISR, are controversial in CD due to:</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>76493</offset><text>• High recurrence rates at surgical sites</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>76537</offset><text>• 80% of postoperative recurrences occurring at the previous surgical site</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>76614</offset><text>• The use of immunosuppressive therapy to prevent recurrence must be carefully weighed against the risk of cancer recurrence</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>76741</offset><text>Even for Hartmann's procedure, where the rectum is preserved, there are concerns:</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>76823</offset><text>• Anastomotic leakage rates in CD bowel anastomosis are relatively high (2.2-4.3%)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>76908</offset><text>• Risk of secondary cancer in the rectal stump must be considered</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>76976</offset><text>Regarding total colectomy in this context, its benefit remains unclear (see CQ14), and decisions regarding extended surgeries, such as pelvic exenteration or multivisceral resections, require further investigation.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>77191</offset><text>CQ19: What is the optimal surgical procedure for CD-associated small bowel cancer?</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>77274</offset><text>Statement</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>77284</offset><text>1. Weakly recommend segmental small bowel resection or ileocecal resection with lymph node dissection. (Recommendation Grade 2, Evidence Level D, Consensus Rate: 86%)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>77451</offset><text>2. Since preoperative diagnosis of CD-associated small bowel cancer is rare, consider intraoperative rapid pathological diagnosis when cancer is clinically or surgically suspected. (Recommendation grade: None; Evidence Level: D)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>77680</offset><text>Comments</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>77689</offset><text>CD-associated small bowel cancer is rare and often not diagnosed preoperatively, making it difficult to compare outcomes by surgical procedure. Unlike sporadic small bowel cancer, which typically occurs in the jejunum, CD-associated cancers predominantly arise in the ileum. Therefore, surgery usually involves segmental small bowel resection or ileocecal resection.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>78056</offset><text>A large retrospective study based on the SEER-Medicare database that included 179 CD-associated small bowel cancer cases among 2,123 patients found no difference in overall survival (OS) between CD-associated and sporadic small bowel cancers. However, greater lymph node retrieval was associated with significantly improved OS. Specifically, compared with no lymph node retrieval, harvesting 10-19 lymph nodes had an HR of 0.51 (95% CI: 0.42-0.61, p &lt; 0.0001).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>78517</offset><text>In a smaller, single-center study of 29 CD-associated small bowel cancer cases, the 2-year survival rate was 79% in node-negative patients, but only 49% in node-positive patients. Thus, lymph node metastasis is likely a prognostic factor, and adequate lymphadenectomy may improve outcomes. Nevertheless, there is currently no evidence-based definition of which lymph nodes should be dissected in small bowel cancer, and no clear recommendations on resection margins or extent of bowel removal.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>79011</offset><text>Due to the high rate (79%-100%) of incidental intraoperative or postoperative diagnosis of CD-associated small bowel cancers, many patients do not undergo sufficient lymphadenectomy when the cancer is not diagnosed before surgery. Moreover, in patients with CD, preservation of small bowel length is prioritized to maintain nutritional absorption, which may lead to suboptimal resection when cancer is unrecognized.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>79427</offset><text>Therefore, if clinical course or intraoperative findings suggest malignancy, intraoperative pathological diagnosis should be considered, even without a confirmed preoperative diagnosis. If cancer is diagnosed intraoperatively, adequate regional lymph node dissection should be performed to improve the prognosis.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>79740</offset><text>Clinical and intraoperative signs suggestive of cancer include:</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>79804</offset><text>• Clinical course: Persistent bowel obstruction not responding to medical therapy, or a long period of remission preceding severe flare-ups requiring hospitalization.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>79973</offset><text>• Intraoperative findings: Palpably hard previous stricture sites, chronic fistulas, nodular changes in omentum or mesentery, and firm, complex small bowel masses.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>80139</offset><text>CQ20: Is minimally invasive surgery recommended for IBD-associated GI cancer?</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>80217</offset><text>Statement</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>80227</offset><text>We weakly recommend laparoscopic surgery for IBD-associated GI cancers. (Recommendation Grade: 2, Evidence Level: D, Consensus Rate: 90%) However, given the high difficulty of the procedure, the proficiency of each surgical team should be fully considered when determining the indication.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>80516</offset><text>Comments</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>80525</offset><text>There is no established evidence regarding the efficacy of minimally invasive surgery (MIS) for IBD-associated GI cancers. Even in several international guidelines on surgical treatment for IBD, the usefulness of MIS for these cancers is not mentioned. Therefore, it is necessary to refer to guidelines and surgical outcomes of similar diseases.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>80871</offset><text>According to a survey conducted by the Japan Society for Endoscopic Surgery, the number of MIS cases up to 2019 was 3,974 for UC and 3,631 for CD, most of which were presumed to be performed laparoscopically. Considering that many MIS cases in IBD are for medically refractory disease, MIS for IBD-associated cancer is likely to be limited to a very small number of cases.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>81244</offset><text>MIS is already widely practiced for sporadic CRC in many facilities. Based on this experience, it is presumed that MIS has been applied to IBD-associated GI cancers in clinical practice, but detailed outcomes have not been clarified. Robotic surgery for IBD remains limited to small case series globally, and its application to IBD-associated GI cancers remains a subject for future research.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>81637</offset><text>Given the rarity of the disease, it is not realistic to conduct large-scale RCTs to clarify the effectiveness of MIS. Surgeons should fully understand both their skills and the disease characteristics and conduct MIS only after obtaining thorough informed consent.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_4</infon><offset>81902</offset><text>UC-associated CRC</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>81920</offset><text>Total colectomy is the standard surgical procedure when UC-associated CRC is identified. However, there are no reports on the perioperative safety and oncological curability of laparoscopic total colectomy with lymph node dissection. The 2020 Guidelines for the Management of Hereditary CRC weakly recommend laparoscopic surgery for familial adenomatous polyposis (FAP), in which total colectomy is also performed when CRC is present. Meanwhile, international and Japanese guidelines recommend laparoscopic total colectomy for medically refractory UC.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>82472</offset><text>A meta-analysis based on 27 observational studies comparing laparoscopic and open total colectomy reported that laparoscopic surgery prolonged operative time by approximately 70 minutes, but reduced blood loss by around 90 g. It also reduced wound infections by about 40%, shortened postoperative hospital stay by around 1 day, and improved bowel function. Furthermore, laparoscopic surgery has been reported to result in fewer intra-abdominal adhesions and better QOL scores. In contrast, reports on robotic surgery are limited. A systematic review found that in robotic total colectomy, only rectal resections used the robot, while colectomies were performed laparoscopically. Retrospective studies reported that the complication rate was comparable to laparoscopic surgery. Although reports on transanal proctectomy combined with laparoscopy are limited, it has been shown that QOL is comparable to laparoscopic-only procedures. It should be noted that none of these studies specifically focused on UC-associated CRC.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>83493</offset><text>Important technical considerations include the potential risk of inadequate lymph node dissection when preserving the ileocolic artery for right-sided colon cancer or when resecting the transverse mesocolon en bloc with energy devices for transverse colon cancer. Furthermore, recent reports have suggested that laparoscopic surgery for rectal cancer may result in inferior surgical quality compared to open surgery. Therefore, MIS should only be performed in highly experienced institutions.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_4</infon><offset>83986</offset><text>CD-associated gastrointestinal cancer</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>84024</offset><text>CD can lead to cancer, not only in the colon, but also in the small intestine and perianal area, making the surgical procedures highly diverse. There are no reports on the perioperative safety or oncological curability of MIS for CD-associated GI cancer. While international and domestic guidelines recommend laparoscopic surgery for CD, they also emphasize that complex or recurrent lesions should be handled by experts. Since CD-associated cancer is considered a complex lesion, the indication for laparoscopic surgery must be carefully considered.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>84575</offset><text>The standard surgical procedure for CD-associated GI cancer is resection of the primary tumor with regional lymph node dissection―principles similar to those of sporadic GI cancer. Hence, results from those cases may be somewhat applicable. The postoperative outcomes and oncological perspectives are summarized as follows:</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_4</infon><offset>84901</offset><text>Postoperative outcomes</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>84924</offset><text>Most MIS studies in CD focus on ileocecal disease. Several RCTs have reported that laparoscopic surgery shortens hospital stay, reduces complications, and lowers costs compared to open surgery. A propensity score-matched study comparing robotic and open ileocecal resection found that robotic surgery helped reduce complications and shorten hospitalization.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_4</infon><offset>85282</offset><text>Oncological perspective</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>85306</offset><text>Although there are no reports on MIS for small bowel cancer, it has been suggested that at least nine lymph nodes should be dissected and examined for proper staging, which should also be met in MIS. For CRC, several RCTs have shown that the long-term outcomes of laparoscopic surgery are comparable to open surgery, and laparoscopic surgery is widely performed.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>85669</offset><text>In particular, CD-associated small bowel cancer is often not diagnosed preoperatively, and its detection during surgery is difficult in laparoscopic procedures due to the lack of tactile sensation. Also, in cases of fistula-associated cancers (e.g., anal fistula cancer), MIS may not achieve adequate resection of the lesion due to the same limitation. Therefore, it is essential to understand the extent of disease and the surgeon's proficiency thoroughly to ensure that oncological curability is not compromised by MIS.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>86191</offset><text>CQ21: Is endoscopic resection recommended for UC-associated colorectal neoplasia?</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>86273</offset><text>Statement</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>86283</offset><text>1. There is no established evidence regarding the safety and long-term prognosis of endoscopic resection for UC-associated colorectal neoplasia. However, as differentiating UC-associated neoplasia from sporadic tumors is not always straightforward, endoscopic resection may be considered for lesions with well-defined margins to establish a definitive diagnosis. (Recommendation grade: None; Evidence Level: D) Nonetheless, for lesions diagnosed as HGD or carcinoma via biopsy, total colectomy is generally recommended. Similarly, if HGD or carcinoma is diagnosed on pathological evaluation after endoscopic resection, total colectomy is also generally recommended (see CQ14).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>86960</offset><text>2. When performing endoscopic resection, en bloc resection using techniques such as ESD or endoscopic mucosal resection (EMR) is recommended for lesions with well-defined margins from the perspective of curative resection. However, these procedures should preferably be performed by experienced endoscopists proficient in colorectal endoscopic resection. (Recommendation grade: None; Evidence Level: D)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>87363</offset><text>3. Endoscopic resection is not recommended for UC-associated colorectal neoplasia with poorly defined margins. (Recommendation grade 2, Evidence level D; Agreement rate: Grade 1: 58%, Grade 2: 27%)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>87561</offset><text>Comments</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>87570</offset><text>There are no RCTs comparing the usefulness of endoscopic resection for UC-associated colorectal neoplasia with other treatment modalities. According to the Surveillance for Colorectal Endoscopic Neoplasia Detection and Management in Inflammatory Bowel Disease Patients: International Consensus Recommendations (SCENIC), endoscopic resection is indicated for neoplastic lesions with well-defined borders. Similarly, an expert review from the American College of Gastroenterology states that dysplastic lesions with clear margins, without signs of invasive cancer or significant submucosal fibrosis, should be considered for endoscopic resection. However, it is important to recognize that these recommendations are based on studies that did not distinguish between UC-associated and sporadic tumors arising in the context of chronic inflammation. Furthermore, these consensus statements are primarily based on studies evaluating outcomes of polypectomy or EMR. In contrast, the Japanese EMR/ESD guidelines do not recommend endoscopic resection for UC-associated colorectal neoplasia.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>88653</offset><text>Among the nine studies underpinning the SCENIC consensus, outcomes of EMR or snare polypectomy for raised lesions in patients with UC showed relatively low rates of progression to CRC or recurrence at follow-up. Nevertheless, since about 50% of lesions were sporadic adenomas (amenable to endoscopic resection), post-treatment surveillance is considered necessary. In contrast, for non-polypoid lesions, there is a lack of studies clearly evaluating recurrence rates after EMR. Additionally, limitations in lesion margin and depth assessment, technical difficulty due to fibrosis, and higher risks of piecemeal or non-curative resection suggest that EMR or polypectomy should not be performed in such cases.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>89361</offset><text>There are currently no studies specifically assessing the outcomes of ESD for UC-associated colorectal neoplasia. The available literature likely includes both UC-associated and sporadic tumors arising in patients with UC, necessitating cautious interpretation of results. Reports from cohort studies show that en bloc resection rates for ESD are relatively high; however, submucosal fibrosis and fat deposition are often observed, requiring advanced technical skill. One case series reported curative resection with ESD for neoplasms arising in the residual rectal mucosa after total colectomy with ileal pouch-anal anastomosis.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>89991</offset><text>Two systematic reviews have evaluated the efficacy and safety of ESD for UC-associated colorectal neoplasia, but these studies also did not distinguish between UC-associated and sporadic tumors. Manta et al. conducted a systematic review including six studies from Japan and Europe involving 208 patients and 216 lesions, reporting R0 resection and en bloc resection rates of 78.2% (95% CI: 72.3-83.2%) and 88.4% (95% CI: 83.5-92.0%), respectively. Complication rates included 6.7% for bleeding and 2.9% for perforation. Recurrence rates were 3.8% for local recurrence and 6.2% for metachronous recurrence. However, this systematic review did not assess the risk of bias, inconsistency, or imprecision across studies, indicating that the evidence is extremely weak.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>90757</offset><text>Chen et al. reviewed seven studies involving 202 cases of endoscopic resection for non-polypoid lesions and found R0 and en bloc resection rates of 0.70 (95% CI: 0.55-0.81) and 0.86 (95% CI: 0.65-0.95), respectively. The recurrence rate was 0.08 (95% CI: 0.05-0.13). Their meta-analysis reported the incidence of CRC and metachronous dysplasia in patients with UC as 32.53 and 90.24 per 1,000 person-years, respectively.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>91178</offset><text>Since accurate differentiation among cancer, HGD, and LGD via endoscopic biopsy is sometimes difficult, endoscopic resection may be performed for well-demarcated lesions to allow for precise pathological diagnosis. However, due to the technical difficulty involved, these procedures should be conducted by specialists experienced in colorectal endoscopic resection. Indications for endoscopic resection include lesions with well-defined borders, absence of surface ulceration, good lifting after submucosal injection, absence of deep invasion, and minimal submucosal fibrosis.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>91755</offset><text>Because synchronous or metachronous recurrence can occur at a certain rate after endoscopic resection, regular endoscopic surveillance is necessary (see CQ22). Even after R0 resection, flat-type residual lesions may remain around the resection margins. Thus, careful follow-up in consultation with experienced pathologists is required. Additionally, if the post-resection pathological diagnosis reveals HGD or CRC, total colectomy is generally recommended (see CQ14).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>92223</offset><text>CQ22: What is the optimal surveillance method after endoscopic resection of UC-associated colorectal neoplasms?</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>92335</offset><text>Statement</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>92345</offset><text>Surveillance with colonoscopy is considered after endoscopic resection of UC-associated colorectal neoplasms; however, the optimal surveillance interval and the efficacy of surveillance methods combining chromoendoscopy or image-enhanced endoscopy remain unclear. (Recommendation grade: None; Evidence Level: D)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>92657</offset><text>Comments</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>92666</offset><text>Dysplasia or CRC has been reported to be detected after endoscopic resection of UC-associated colorectal neoplasms. A recent systematic review involving 208 cases and 216 lesions treated by endoscopic resection reported metachronous recurrence in eight cases (3.8%, 95% CI 2.0-7.4%) and 13 lesions (6.2%, 95% CI 3.7-10.4%) after treatment.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>93006</offset><text>Currently, even after R0 resection, total colectomy is generally recommended when pathological diagnosis after endoscopic resection reveals HGD or colorectal cancer. For LGD, the risk of synchronous and metachronous colorectal cancer is relatively low compared to HGD; therefore, regular colonoscopic surveillance without total colectomy may be considered after endoscopic resection.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>93390</offset><text>The prognosis after endoscopic resection―mainly EMR or polypectomy―of 376 elevated lesions showed a colorectal cancer incidence of 0.5% per year during a mean follow-up period of 54 months. The Surveillance for Colorectal Endoscopic Neoplasia Detection and Management in Inflammatory Bowel Disease Patients: International Consensus Recommendations (SCENIC) strongly recommends surveillance over colectomy if endoscopic curative resection is achieved for elevated lesions. In such cases, colonoscopy is recommended every 3-6 months post-resection; if no lesions are detected, surveillance intervals may then be extended.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>94014</offset><text>It is considered that lesions targeted by this recommendation include both UC-associated colorectal neoplasms, such as LGD, as well as sporadic adenomas. As distinguishing between the two is challenging, strict surveillance based on UC-associated neoplasms is considered necessary. In contrast, surveillance after curative endoscopic resection of non-polypoid lesions is weakly recommended. This difference in recommendation strength stems from the technical difficulty of endoscopic resection of non-polypoid lesions and the potentially higher risk of recurrence.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>94579</offset><text>Although evidence regarding surveillance methods after endoscopic resection is lacking, considering the high risk of metachronous development of UC-associated colorectal neoplasms, surveillance using high-definition colonoscopy is recommended, with the addition of chromoendoscopy or image-enhanced endoscopy as needed.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>94899</offset><text>CQ23: What are the considerations for IBD medication management after surgery for IBD-associated GI cancer?</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>95007</offset><text>Statement</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>95017</offset><text>In patients who require immunosuppressive therapy after surgery for IBD-associated GI cancer, treatment decisions should be made on a case-by-case basis considering safety and efficacy, after discussion among gastroenterologists, oncologists, and surgeons, with careful attention to the risk of cancer recurrence. (Recommendation grade: None; Evidence Level: D)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>95379</offset><text>Comments</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>95388</offset><text>Immunosuppressive treatments, such as biologics, are sometimes used for pouchitis or for prevention of postoperative recurrence in CD.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>95523</offset><text>In organ transplant recipients, long-term use of immunomodulators like thiopurines and calcineurin inhibitors has been reported to increase the risk of new cancer development and cancer recurrence. Based on these data, there is concern that immunosuppressive treatments, including immunomodulators and biologics, may increase the risk of cancer recurrence after surgery for IBD-associated GI neoplasia.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>95926</offset><text>Although there are no studies specifically evaluating the impact of IBD medications on cancer recurrence after treatment for IBD-associated GI cancer, one retrospective study compared cancer incidence and recurrence rates between immunosuppressed and non-immunosuppressed patients with IBD with a history of cancer. This study, which included patients with IBD with prior GI neoplasia, skin tumors, hematologic malignancies, and other solid tumors, found no significant effect of immunosuppressive therapy on new cancer development or recurrence (immunomodulators: HR 1.08, 95% CI 0.54-2.15; anti-TNF-α antibodies: HR 0.32, 95% CI 0.09-1.09; combination therapy: HR 0.64, 95% CI 0.26-1.59). No studies have specifically assessed the impact of immunosuppressive therapy on cancer recurrence in patients with IBD with a history of GI cancer.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>96770</offset><text>A meta-analysis published in 2016 evaluating 16 studies (9 rheumatoid arthritis, 8 IBD, 1 psoriasis) examined cancer recurrence in patients with a history of cancer treated with immunosuppressants (anti-TNF-α antibodies, immunomodulators). This analysis reported no significant difference in new cancer incidence or recurrence rates between patients treated with immunosuppressive therapy and untreated patients, including those with non-melanoma skin cancer and breast cancer (incidence rates per 1,000 person-years: immunomodulators 36.2 [95% CI 17.7-54.7], anti-TNF-α antibodies 33.8 [95% CI 22.3-45.2], combination therapy 54.5 [95% CI 29.7-79.3], no immunosuppression 37.5 [95% CI 20.2-54.7]).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>97477</offset><text>Similarly, a 2019 meta-analysis of nine studies (8 rheumatoid arthritis, 2 IBD) found no significant effect of anti-TNF-α antibody therapy on new cancer incidence or recurrence (incidence rate ratio 0.90, 95% CI 0.59-1.37).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>97705</offset><text>No systematic reviews or meta-analyses have evaluated the impact of ustekinumab, vedolizumab, or tofacitinib in patients with a history of cancer. Vedolizumab, which selectively acts on the gut, is considered to have the highest safety profile based on its mechanism of action.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>97983</offset><text>Long-term systemic corticosteroid use has been associated with increased risks of lymphoma and non-melanoma skin cancer, although no data exist regarding the risk of cancer recurrence after GI cancer treatment in patients with IBD using systemic steroids. According to ECCO guidelines, short-term systemic corticosteroids may be considered in patients with active IBD and a history of cancer on a case-by-case basis. 5-Aminosalicylic acid (5-ASA), nutritional therapy, and topical steroids are generally considered safe.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>98504</offset><text>To date, meta-analyses have not clarified the impact of immunosuppressive therapy on cancer recurrence in patients with a history of cancer, suggesting that immunosuppressive therapy should not be uniformly prohibited in patients with IBD with a history of cancer. However, the possibility of an increased risk of cancer recurrence affected by immunosuppressive therapy cannot be completely ruled out. ECCO guidelines recommend avoiding immunosuppressive therapy for at least 2 years after cancer treatment completion, and for 5 years in patients with moderate-to-high recurrence risk.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>99090</offset><text>In patients after surgery for IBD-associated GI cancer, immunosuppressive therapy should generally be initiated only after completion of cancer treatment. When immunosuppressive therapy is necessary, treatment plans should be decided considering safety and efficacy through multidisciplinary discussion among gastroenterologists, oncologists, and surgeons on a case-by-case basis, taking into account the risk of cancer recurrence.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>99522</offset><text>CQ24: Is adjuvant chemotherapy recommended after surgery for IBD-associated GI neoplasia?</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>99612</offset><text>IBD-associated colorectal neoplasia</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>99648</offset><text>The efficacy of adjuvant chemotherapy after surgery cannot be determined. Appropriateness should be judged on a case-by-case basis. (Recommendation grade: None; Evidence Level: D)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>99828</offset><text>CD-associated small intestinal neoplasia</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>99869</offset><text>The efficacy of adjuvant chemotherapy after surgery cannot be determined. (Recommendation grade: None; Evidence Level: D)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>99991</offset><text>Explanation</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>100003</offset><text>There are no RCTs comparing the usefulness of adjuvant chemotherapy after treatment for IBD-associated gastrointestinal neoplasia between treated and untreated groups. Although the number of patients with IBD is increasing, the number in Japan is approximately 200,000 with UC and 70,000 with CD, and only a subset of these develop GI neoplasia. In contrast, sporadic CRC cases exceed 100,000 annually, making IBD-associated GI neoplasia very rare. Furthermore, large individual variations in inflammation severity, lesion extent, nutritional status, and effects of total colectomy in patients with UC make conducting prospective observational studies extremely difficult.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_4</infon><offset>100676</offset><text>IBD-associated colorectal neoplasia</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>100712</offset><text>Reports of chemotherapy use for IBD-associated CRC are very limited. One United States report describes adjuvant chemotherapy administered to 27 patients with UC-associated colorectal cancer, but details on regimen, adverse events, or outcome comparisons were not provided. Another report summarized 82 colorectal cancer cases treated with hand-sewn IPAA, including UC and familial adenomatous polyposis cases; among 16 patients who received chemotherapy, two had diarrhea and one had hepatitis leading to dose reduction or discontinuation. A French report on 34 IBD-associated CRC cases showed that 15 received adjuvant chemotherapy, but regimens and adverse events were unspecified.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>101397</offset><text>A multicenter study comparing outcomes of patients with rectal cancer patients with and without IBD (matched for stage and age) showed no prognostic difference; however, adjuvant chemotherapy was given less frequently in patients with IBD-associated rectal cancer (46% vs. 56%, p = 0.083), and its efficacy was not specifically evaluated.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>101736</offset><text>A Japanese report on chemotherapy in 29 patients with IBD-associated CRC (18 UC, 11 CD) showed that 16 received adjuvant chemotherapy regimens, including FOLFOX (5-FU+leucovorin+oxaliplatin) therapy, CapeOX (capecitavine+oxaliplatin) therapy, S-1, capecitabine, and UFT+LV (tegafur uracil+leucovorin) therapy. Dose reduction was required in 31%, mostly due to hematologic toxicity (50%), fatigue (17%), hand-foot syndrome (17%), and increased creatinine (17%). Only 44% completed adjuvant chemotherapy, and grade 3/4 adverse events were most commonly neutropenia (19%). However, the number of cases per regimen was small.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>102358</offset><text>There is also a case report of a 47-year-old patient with CD with cecal cancer who received postoperative FOLFOX therapy, but prognosis and adverse events were not described.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>102533</offset><text>Given the limited data, criteria to judge the appropriateness of adjuvant chemotherapy for IBD-associated colorectal neoplasia do not exist. At present, the efficacy of postoperative adjuvant chemotherapy cannot be determined. However, since IBD-associated colorectal neoplasia often occur in younger patients, reducing postoperative recurrence risk is important. Therefore, decisions on adjuvant chemotherapy should consider cancer stage, recurrence risk, as well as the patient's overall condition, nutritional status, age, severity and extent of IBD inflammation, and treatment details and response.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_4</infon><offset>103136</offset><text>CD-associated small intestinal neoplasia</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>103177</offset><text>No publications exist on adjuvant chemotherapy for CD-associated small intestinal neoplasia, so its appropriateness cannot be determined.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>103315</offset><text>CQ25: Is drug therapy recommended for advanced or recurrent IBD-associated GI cancer?</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>103401</offset><text>Drug therapy for advanced or recurrent IBD-associated GI cancer is weakly recommended when the patient's general condition is good and major organ functions are preserved, although its efficacy equivalent to that for sporadic GI cancer has not been demonstrated. (Recommendation level 2, Evidence level C, Agreement rate: 86%)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>103728</offset><text>Comments</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>103737</offset><text>The goal of drug therapy for advanced or recurrent IBD-associated GI cancer is to delay cancer progression and achieve life prolongation and symptom control. There are no meta-analyses, RCTs, or prospective cohort studies comparing the efficacy of drug therapy for advanced or recurrent IBD-associated GI cancer with sporadic GI cancer. In Japan, treatment generally follows guidelines for CRC, which is the main type of IBD-associated GI cancer, with decisions on indication and regimen selection based on assessment of general condition and major organ function. When administering drug therapy, attention must be paid to adverse events such as GI and hematologic toxicities, and IBD activity should be monitored appropriately.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_4</infon><offset>104467</offset><text>Efficacy of drug therapy for advanced or recurrent IBD-associated GI cancer</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>104543</offset><text>A retrospective case-control study matched 18 cases of advanced or recurrent IBD-associated GI cancer (15 CRC, 3 small intestinal cancer) with sporadic GI cancer cases based on background and drug regimen. The objective response rates to first-line treatment (FOLFOX therapy or FOLFOX+bevacizumab therapy in nine cases, FOLFIRI therapy or FOLFIRI+bevacizumab therapy in 6, 5-FU+leucovorin therapy in 3, FOLFOX therapy +hepatic arterial infusion in 1) showed no significant difference (35.7% vs. 57.1%, p = 0.45), but the IBD-associated group had significantly shorter median response duration (1.4 vs. 11.8 months, p = 0.006) and median survival time (MST) (13.5 vs. 27.6 months, p = 0.034).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>105235</offset><text>Another retrospective case-control study compared 80 cases of IBD-associated colorectal cancer (55 UC, 25 CD) with 78 sporadic colorectal cancer cases matched for background, cancer stage, and treatment regimen, and reported significantly lower 5-year survival in stage IV IBD-associated cases (19% vs. 50%, p = 0.017).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>105555</offset><text>A Japanese retrospective study of 29 IBD-associated CRC cases (18 UC, 11 CD) reported a response rate of 15%, median progression-free survival (PFS) of 182 days, and MST of 315 days among 13 patients receiving palliative chemotherapy (6 FOLFOX therapy, 3 FOLFOX+bevacizumab therapy, 4 others).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>105849</offset><text>A review focusing on mucinous CRC, often seen in IBD-associated cases, found that all four case-control studies reported significantly worse OS in mucinous cancer compared to non-mucinous cancer.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_4</infon><offset>106045</offset><text>Tolerance and adverse events of drug therapy</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>106090</offset><text>In the above retrospective study, treatment delays, interruptions, and dose reductions were significantly more frequent in IBD-associated CRC cases (74% vs. 44%, p = 0.03), mainly due to GI toxicities including diarrhea, enteritis, and ileus. Another study reported grade 3/4 adverse events in 55% of patients, with 38% requiring dose reduction.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>106436</offset><text>A retrospective study on eight IBD-associated GI cancer patients (3 UC, 5 CD) found diarrhea as the most frequent GI toxicity (75%), with all grade 3 diarrhea occurring in patients with CD; hematologic toxicities included anemia (75%), lymphopenia (38%), and neutropenia (30%), with grade 3 neutropenia in 25%.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_4</infon><offset>106747</offset><text>Drug therapy and IBD disease control</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>106784</offset><text>It is desirable that IBD disease activity be controlled during drug therapy to preserve major organ function. One report found grade 3/4 GI toxicity was significantly higher during IBD active phase than remission (57% vs. 5%, p &lt; 0.01). Another report found no effect of IBD activity on treatment delays or dose reductions, but distinguishing drug-induced GI toxicity from IBD symptoms can be difficult.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>107188</offset><text>Some opinions suggest that immunosuppressive effects of chemotherapy might control IBD activity, but the impact of drug therapy on IBD disease course remains unclear. The ECCO malignancy consensus recommends that 5-aminosalicylic acid (5-ASA) agents, nutritional therapy, and local steroids are safe even in cancer-bearing states, while thiopurines, calcineurin inhibitors, and anti-TNF-α antibody should be avoided during chemotherapy (see CQ23). However, IBD flares may require deviation from this, and multidisciplinary discussion among gastroenterologist, oncologists, and surgeons is important for individualized treatment decisions.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>107831</offset><text>CQ26: Is neoadjuvant chemoradiotherapy effective for IBD-associated rectal cancer?</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>107914</offset><text>Statement</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>107924</offset><text>The efficacy and safety of neoadjuvant chemoradiotherapy for IBD-associated rectal cancer have not been established. (Recommendation grade: No recommendation; Evidence level C)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>108101</offset><text>Comments</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>108110</offset><text>Neoadjuvant chemoradiotherapy for rectal cancer has been widely used, especially in Western countries, with the aim of improving OS in R0 resectable cases, reducing local recurrence rates, and enabling sphincter preservation through tumor shrinkage. In Japan, total mesorectal excision (TME) or tumor-specific mesorectal excision with lateral lymph node dissection is the standard treatment for advanced lower rectal cancer, yielding favorable outcomes. However, clear evidence is lacking regarding the additional benefit of neoadjuvant chemoradiotherapy in reducing local recurrence or as an alternative to lateral lymph node dissection. Accordingly, the Japanese CRC treatment guidelines weakly recommend neoadjuvant chemoradiotherapy for rectal cancers with a high risk of local recurrence (Recommendation level 2, Evidence level B). For unresectable locally advanced rectal cancers without distant metastasis, chemoradiotherapy aimed at tumor shrinkage to enable R0 resection is also weakly recommended (Recommendation level 2, Evidence level B).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>109161</offset><text>However, reports on neoadjuvant chemoradiotherapy specifically for IBD-associated rectal cancer are limited, and its use requires careful consideration of the effectiveness of chemoradiotherapy, the underlying IBD treatment and activity, and the safety of the planned surgery.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>109438</offset><text>Many reports indicate that neoadjuvant chemoradiotherapy can be safely performed in this population. Cases of chemoradiotherapy for fistula-associated anal cancer in patients with CD have also been reported. In contrast, radiation exposure to the intestines of patients with UC has been reported to cause more adverse effects than to those of non-IBD, and exacerbation of IBD during chemoradiotherapy has also been reported, necessitating greater caution than in usual rectal cancer treatment.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>109932</offset><text>Regarding surgery after chemoradiotherapy, complications related to the perineal wound and delayed healing have been reported, but these are not specific to IBD-associated rectal cancer, and there is no evidence that complication risk is increased. Some studies have reported that neoadjuvant chemoradiotherapy increases the incidence of chronic pouchitis and pouch failure, and pelvic radiation before hand-sewn IPAA is considered to be associated with postoperative functional disorders.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>110422</offset><text>In terms of efficacy, neoadjuvant chemoradiotherapy for IBD-associated rectal cancer is thought to be comparable to that for sporadic rectal cancer. However, no reports have demonstrated improved OS or reduced local recurrence rates in IBD-associated rectal cancer. Compared with sporadic rectal cancer, IBD-associated rectal cancer shows significantly lower rates of neoadjuvant chemoradiotherapy use, higher rates of circumferential resection margin (CRM) positivity, and trends toward worse overall and relapse-free survival. Nevertheless, sufficient data are lacking, and the efficacy and safety remain unestablished.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>111044</offset><text>CQ27: Is the prognosis of IBD-associated GI cancer worse than that of sporadic GI cancer?</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>111134</offset><text>Statement</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_4</infon><offset>111144</offset><text>IBD-associated CRC</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>111163</offset><text>IBD-associated CRC has a worse prognosis compared to sporadic CRC. (Evidence level B)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_4</infon><offset>111249</offset><text>CD-associated small intestinal cancer</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>111287</offset><text>CD-associated small intestinal cancer has a poor prognosis; however, direct comparison with sporadic small bowel cancer is difficult due to differences in tumor location and its frequency. (Evidence level C)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>111495</offset><text>Comments</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>111504</offset><text>Meta-analyses comparing the prognosis of IBD-associated CRC with sporadic CRC were published in 2016, 2017, and 2022. The recent meta-analysis, which integrated data from 25 studies, found that IBD-associated CRC was associated with significantly worse prognosis (HR 1.33; 95% CI: 1.20-1.40), which resolved the controversy between the 2016 and the 2017 meta-analytic studies. Subgroup analyses also confirmed worse outcomes for both UC-associated and CD-associated CRCs compared to sporadic cases.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>112003</offset><text>A large cohort study from Sweden and Denmark, published in 2020 and including nearly 100,000 individuals, reported that although IBD-associated CRCs were diagnosed at an earlier stage, OS was lower than in sporadic CRCs.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>112224</offset><text>IBD-associated CRCs tend to exhibit more aggressive histological features, such as signet ring cell carcinoma. Molecularly, sporadic CRCs typically harbor early APC mutations and later TP53 mutations, whereas IBD-associated cancers often present with early TP53 mutations and fewer APC mutations, reflecting distinct genetic pathways. Advances in cancer genomic medicine may improve the prognosis of IBD-associated GI cancers in the future.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_4</infon><offset>112665</offset><text>UC-associated CRC</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>112683</offset><text>UC-associated CRC has a worse prognosis than sporadic CRC. In the recent meta-analysis, 10 studies comparing UC-associated CRC and sporadic CRC showed a pooled HR of 1.35 (95% CI: 1.16-1.57), indicating poorer outcomes in the UC group. A multicenter Japanese study analyzing 238 cases of UC-associated CRC reported 5-year survival rates of 93.9% for Stage I, 90.7% for Stage II, 62.2% for Stage III (76.8% for IIIa, 38.0% for IIIb, and 29.6% for IIIc), and 8.4% for Stage IV disease.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>113167</offset><text>Comparing prognosis between IBD-associated and sporadic cancers should ideally involve stage-specific analyses within the same population during the same period. A nationwide Japanese study reported that UC-associated CRC had a significantly worse prognosis than sporadic CRC at Stage III (5-year survival: 43.3% vs. 57.4%; p = 0.0320).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_4</infon><offset>113504</offset><text>CD-associated GI cancer</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>113528</offset><text>CD-associated CRC has a worse prognosis than sporadic CRC. While CD-associated small bowel cancer also has a poor prognosis, the anatomical distribution of tumors differs from that of sporadic cases, making direct comparisons difficult. In the recent meta-analysis, all five included studies reported significantly worse outcomes for CD-associated CRC, with a pooled HR of 1.32 (95% CI: 1.24-1.40).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>113927</offset><text>Although no Japanese studies were included in that meta-analysis, a Japanese single-center cohort study reported a standardized mortality ratio (SMR) for CRC in patients with CD of 29.7 (95% CI: 16.5-53.7), indicating significantly higher mortality compared to the general population. A Japanese multicenter study also reported poor prognosis in CD-associated GI cancers, even though no comparison with the general population was made. In this study, based on 119 analyzable cases (including 10% small bowel cancers and 51% anal canal cancers), 5-year survival rates were 88% for Stage I, 68% for Stage II, 71% for Stage IIIa, 25% for Stage IIIb, and 0% for Stage IV.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>114595</offset><text>CD-associated GI cancers can arise throughout the GI tract, including the small intestine, colon, rectum, anus, and even fistulas. In Western countries, a higher proportion of right-sided colon cancers compared to sporadic cases has been noted (see CQ3), and colonoscopic surveillance is recommended. In Japan, CD-associated cancers more commonly arise in the anorectal region, including anal fistulas, showing a different anatomical distribution from Western cases. Early detection of anorectal and small bowel cancers in CD is challenging, and poor prognosis is common. In addition to endoscopic surveillance, some specialized centers in Japan perform biopsies of the anorectal area under anesthesia to improve early detection (see CQ9).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>115335</offset><text>A 2022 meta-analysis of 879 CD-associated small intestinal cancer cases reported a 5-year OS rate of 29% (95% CI: 0.18-0.41), indicating poor outcomes. Although this analysis also attempted to compare prognosis with sporadic small intestinal cancers, not all included studies had matched control groups, and many included duodenal cancers, limiting the interpretability of the results. One study from the U.S. National Cancer Database excluded duodenal cancers and analyzed 493 CD-associated and 2,175 sporadic small intestinal cancer cases. The 5-year OS rates were 41.1% for CD-associated and 35.4% for sporadic small intestinal cancer (p = 0.09), with no statistically significant differences found in stage-specific analyses. Differences in tumor location―ileal predominance in CD versus duodenal/jejunal predominance in sporadic cases―further complicate direct prognostic comparisons.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>116229</offset><text>CQ28: Do patients with IBD have an increased risk of developing extraintestinal malignant tumor?</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>116326</offset><text>Statement</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>116336</offset><text>1. Overall risk of extraintestinal malignancies in patients with IBD is significantly increased compared to the general population. (Evidence level B)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>116487</offset><text>2. Patients with IBD have increased risks of hepatobiliary cancer, hematologic malignancies, and skin cancers (both non-melanoma skin cancer [NMSC] and melanoma). (Evidence level B)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>116669</offset><text>Comments</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>116678</offset><text>Regarding the risk of extraintestinal malignancies in patients with IBD, two systematic reviews summarizing population-based cohort studies have been published. In a meta-analysis by Pedersen et al. including eight cohort studies up to 2009, the overall risk of extraintestinal malignancies in patients with IBD was comparable to that in the general population (SIR 1.10; 95% CI, 0.96-1.27). However, a meta-analysis by Lo et al., including 15 population-based cohort studies up to 2020, found a significantly increased overall risk of extraintestinal malignancies in both CD (incidence rate ratio [IRR] 1.43; 95% CI, 1.26-1.63) and UC (IRR 1.15; 95% CI, 1.02-1.31). Furthermore, increased risks were noted for specific malignancies such as hepatobiliary cancer, hematologic malignancies, skin cancers (NMSC and melanoma), and lung cancer.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>117518</offset><text>The risk of biliary tract cancer in patients with IBD is significantly elevated in both UC (IRR 2.93; 95% CI, 1.73-4.98) and CD (IRR 2.93; 95% CI, 1.16-7.41). Risk factors associated with biliary tract cancer include early-onset disease, male sex, long disease duration, and comorbid PSC, as reported in individual cohort studies. Notably, patients with PSC have increased risks of cholangiocarcinoma (HR 28.46), hepatocellular carcinoma (HR 21.00), pancreatic cancer (HR 5.26), and gallbladder cancer (HR 9.19).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>118031</offset><text>The risk of hematologic malignancies, particularly lymphoma, is significantly increased in patients with CD (all hematologic malignancies: IRR 2.40; 95% CI, 1.81-3.18; lymphoma: IRR 1.86; 95% CI, 1.04-3.32), but not in patients with UC. No increased risk has been reported for specific subtypes of hematologic malignancies in either CD or UC. However, the risk of non-Hodgkin lymphoma is particularly elevated in patients with CD, and its association with thiopurines use has been reported. Conversely, a Japanese study using a Diagnosis Procedure Combination (DPC) database involving 75,673 patients with IBD found no increased incidence of lymphoma with thiopurine use.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>118703</offset><text>Many reports, including meta-analyses, have shown an increased risk of NMSC in both patients with CD and UC (CD: IRR 2.28; 95% CI, 1.36-3.81; UC: IRR 1.36; 95% CI, 1.05-1.77). Immunomodulators, in particular, have been reported as risk factors for NMSC. However, the incidence of NMSC in the Japanese population is lower than in Western countries, and careful risk-benefit consideration is recommended when prescribing thiopurines.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>119135</offset><text>Regarding melanoma, one meta-analysis reported an increased risk only in patients with CD (IRR 1.52; 95% CI, 1.03-2.23), while two others suggested increased risks in both UC and CD. Further studies with larger sample sizes are warranted. Anti-tumor necrosis factor-α (TNF-α) therapy has been reported as a risk factor for melanoma development, and ECCO guidelines recommend avoiding anti-TNF-α agents in patients with IBD with a history of melanoma.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>119598</offset><text>In terms of lung cancer, Lo et al.'s meta-analysis reported an increased risk in patients with CD (IRR 1.53; 95% CI, 1.23-1.91). However, only 2 of 16 included cohort studies showed a statistically significant increase, indicating the need for cautious interpretation. No increased risk has been reported for malignancies of the renal/urinary tract or reproductive organs (cervix, uterus, ovaries, breast, prostate) according to the results of meta-analyses.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>120057</offset><text>How to Use This Guideline</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>120083</offset><text>This guideline has been developed based on evidence obtained from a comprehensive literature review, while also considering the realities of Japan's medical insurance system and clinical practice. It reflects the consensus of the JSCCR and the Japanese Inflammatory Bowel Disease Research Group.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>120379</offset><text>It serves as a practical tool for clinicians treating IBD-associated GI cancers. Specifically, it can be used as a reference when determining treatment plans for individual cases and in obtaining informed consent from patients.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>120607</offset><text>However, this guideline is not intended to regulate or limit other diagnostic or therapeutic approaches beyond those described herein. It may also be used to explain and justify clinical decisions that differ from the recommendations in this document.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>120859</offset><text>While the JSCCR assumes responsibility for the content of this guideline, the ultimate responsibility for treatment outcomes lies with the attending physician. Neither the JSCCR nor the Guideline Committee bears responsibility for individual clinical outcomes.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>121120</offset><text>Conclusion</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>121131</offset><text>Here we presented the English version of the JSCCR Guidelines 2024 for the Clinical Practice of Inflammatory Bowel Disease-Associated Intestinal Neoplasia. This guideline has been developed with the following objectives: (1) to clarify the current knowledge and remaining issues concerning the diagnosis and treatment of malignancies (mainly GI cancers) associated with IBD; (2) to provide non-specialist clinicians with an understanding of the current state of medical care for IBD-associated tumors, thereby facilitating cooperation with specialists; (3) to help IBD specialists recognize the current standard of care and outstanding issues; and (4) to ultimately improve clinical outcomes in patients with IBD-associated GI neoplasms. Although the evidence in this area is limited, and the clinical features and real-world practices of IBD-associated intestinal neoplasia may differ between Japan and other countries, we hope that these guidelines will be helpful to all healthcare professionals involved in the care of patients with IBD.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>122173</offset><text>Conflicts of Interest</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>122195</offset><text>COIs were confirmed through self-reporting by all committee members. The following companies were declared:</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>122303</offset><text>Asahi Kasei Medical Co., Ltd., Astellas Pharma Inc., AstraZeneca K.K., AbbVie GK, Ayumi Pharmaceutical Corporation, Alfresa Pharma Corporation, EA Pharma Co., Ltd., EP-CRUZ Co., Ltd., Kinshukai Medical Corporation, Midtown Clinic Medical Corporation, Viatris Pharmaceuticals Japan, Olympus Corporation, Otsuka Pharmaceutical Factory, Inc., JIMRO Co., Ltd., Yakult Honsha Co., Ltd., Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Gilead Sciences, Inc., Zeria Pharmaceutical Co., Ltd., Celgene K.K., Daiichi Sankyo Company, Limited, Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Nippon Kayaku Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Pfizer Japan Inc., Bristol Myers Squibb K.K., HOYA Pentax Medical, Mylan EPD GK, Mochida Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>123224</offset><text>Disclaimer</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>123235</offset><text>Soichiro Ishihara is an Editor-in-Chief and Yutaka Saito and Koji Okabayashi are the Associate Editors of Journal of the Anus, Rectum and Colon and on the journal's Editorial Board. They were not involved in the editorial evaluation or decision to accept this article for publication at all.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>123527</offset><text>COI Management</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>123542</offset><text>To minimize bias, the committee was composed of members from diverse specialties, including internal medicine, surgery, and pathology. Recommendation decisions were based on a consensus-building process through voting by all members, excluding the chair. COIs―both financial and academic―were checked for each CQ, and members with relevant COIs were instructed to abstain from voting.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>123931</offset><text>JSCCR Guidelines 2024 for the Clinical Practice of Inflammatory Bowel Disease-Associated Intestinal Neoplasia; 2024 (Japanese). Kanehara, Tokyo.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>124076</offset><text>Minds Guideline Development Manual 2020 ver. 3.0. Tokyo: Japan Council for Quality Health Care; 2020 (Japanese).</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>124189</offset><text>Harpaz N, Talbot IC. Colorectal cancer in idiopathic inflammatory bowel disease. Semin Diagn Pathol. 1996 Nov;13(4):339-57.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>124313</offset><text>Bernstein CN, Blanchard JF, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001 Feb 15;91(4):854-62.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>124476</offset><text>Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001 Apr;48(4):526-35.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>124608</offset><text>Itzkowitz SH, Yio X. Inflammation and Cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004 Jul;287(1):G7-17.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>124796</offset><text>Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology. 2011 May;140(6):1807-16.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>124900</offset><text>Saraggi D, Fassan M, Mescoli C, et al. The molecular landscape of colitis-associated carcinogenesis. Dig Liver Dis. 2017 Apr;49(4):326-30.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>125039</offset><text>Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol. 1983 Apr;14(11):931-68.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>125228</offset><text>Velayos FS, Loftus EV Jr, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology. 2006 May;130(7):1941-9.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>125424</offset><text>Schneider A, Stolte M. Differential diagnosis of adenomas and dysplastic lesions in patients with ulcerative colitis. Z Gastroenterol. 1993 Nov;31(11):653-6.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>125582</offset><text>Odze RD. Adenomas and adenoma-like DALMs in chronic ulcerative colitis: a clinical, pathological, and molecular review. Am J Gastroenterol. 1999;94(7):1746-50.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>125742</offset><text>Vieth M, Neumann H. Current issues in inflammatory bowel disease neoplasia. Histopathology. 2015 Dec;66(1):37-48.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>125856</offset><text>Odze RD, Riddell RH, Bosman FT, et al. WHO classification of tumours of the digestive system. 4th ed. Lyon: IARC; 2010. Premalignant lesions of the digestive system; pp. 10-2, Bosman, FT, Carneiro, F, Hruban, RH, et al., eds.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>126082</offset><text>van Rheenen PF, Aloi M, Biron IA, et al. European Crohn's and colitis organisation topical review on transitional care in inflammatory bowel disease. J Crohns Colitis. 2017 Oct;11(9):1032-8.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>126273</offset><text>Tranter-Entwistle I, Mullaney TG, Noah K, et al. Long-term incidence of dysplasia and colorectal cancer in an ulcerative colitis population-based cohort. ANZ J Surg. 2020 Apr;90(5):821-5.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>126461</offset><text>Matsuoka H, Ikeuchi H, Uchino M, et al. Clinicopathological features of ulcerative colitis-associated colorectal cancer pointing to efficiency of surveillance colonoscopy in a large retrospective Japanese cohort. Int J Colorectal Dis. 2013 Apr;28(6):829-34.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>126719</offset><text>Bogach J, Pond G, Eskicioglu C, et al. Age-related survival differences in patients with inflammatory bowel disease-associated colorectal cancer: a population-based cohort study. Inflamm Bowel Dis. 2019 Oct;25(12):1957-65.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>126942</offset><text>Kunovszki P, Milassin Á, Gimesi-Országh J, et al. Epidemiology, mortality and prevalence of colorectal cancer in ulcerative colitis patients between 2010-2016 in Hungary - a population-based study. PLoS One. 2020 Mar;15(5):e0233238.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>127177</offset><text>Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019 Apr;68(suppl 3):S1-106.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>127364</offset><text>Beaugerie L, Svrcek M, Seksik P, et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology. 2013 Oct;145(1):166-75.e8.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>127583</offset><text>Torres J, Pineton de Chambrun G, Itzkowitz S, et al. Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. Aliment Pharmacol Ther. 2011 Jan;34(5):497-508.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>127801</offset><text>Lutgens M, Vermeire S, Van Oijen M, et al. A rule for determining risk of colorectal cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2015 Dec;13(1):148-54.e1.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>127992</offset><text>Cohen-Mekelburg S, Schneider Y, Gold S, et al. Risk of early colorectal cancers needs to be considered in inflammatory bowel disease care. Dig Dis Sci. 2019 Oct;64(8):2273-9.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>128167</offset><text>Hata K, Anzai H, Ikeuchi H, et al. Surveillance colonoscopy for ulcerative colitis-associated colorectal cancer offers better overall survival in real-world surgically resected cases. Am J Gastroenterol. 2019 Nov;114(3):483-9.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>128394</offset><text>Heuschen UA, Hinz U, Allemeyer EH, et al. Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. Gastroenterology. 2001 Jan;120(4):841-7.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>128566</offset><text>Navaneethan U, Jegadeesan R, Gutierrez NG, et al. Backwash ileitis and the risk of colon neoplasia in ulcerative colitis patients undergoing restorative proctocolectomy. Dig Dis Sci. 2013 Oct;58(7):2019-27.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>128773</offset><text>Stellingwerf ME, Bemelman WA, Löwenberg M, et al. A nationwide database study on colectomy and colorectal cancer in ulcerative colitis: what is the role of appendectomy? Colorectal Dis. 2021 Oct;23(1):64-73.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>128982</offset><text>Stellingwerf ME, de Koning MA, Pinkney T, et al. The risk of colectomy and colorectal cancer after appendectomy in patients with ulcerative colitis: a systematic review and meta-analysis. J Crohns Colitis. 2019 Oct;13(3):309-18.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>129211</offset><text>Gordillo J, Cabré E, Garcia-Planella E, et al. Thiopurine therapy reduces the incidence of colorectal neoplasia in patients with ulcerative colitis. Data from the ENEIDA registry. J Crohns Colitis. 2015 Oct;9(12):1063-70.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>129434</offset><text>Olén O, Erichsen R, Sachs MC, et al. Colorectal cancer in Crohn's disease: a Scandinavian population-based cohort study. Lancet Gastroenterol Hepatol. 2020 Oct;5(5):475-84.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>129608</offset><text>Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther. 2006 Apr 15;23(8):1097-104.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>129782</offset><text>Beaugerie L, Carrat F, Nahon S, et al. High Risk of Anal and Rectal Cancer in Patients with Anal and/or Perianal Crohn's disease. Clin Gastroenterol Hepatol. 2018 Jun;16(6):892-9.e2.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>129965</offset><text>Watanabe T, Konishi T, Kishimoto J, et al. Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: a nationwide Japanese study. Inflamm Bowel Dis. 2011 May;17(3):802-8.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>130183</offset><text>Burmer GC, Rabinovitch PS, Haggitt RC, et al. Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. Gastroenterology. 1992 Oct;103(5):1602-10.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>130368</offset><text>Robles AI, Traverso G, Zhang M, et al. Whole-exome sequencing analyses of inflammatory bowel disease-associated colorectal cancers. Gastroenterology. 2016 Jun;150(4):931-43.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>130542</offset><text>Klampfer L. Cytokines, inflammation and colon cancer. Curr Cancer Drug Targets. 2011 May;11(4):451-64.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>130645</offset><text>Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019 Mar;114(3):384-413.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>130792</offset><text>Magro F, Gionchetti P, Eliakim R, et al. European Crohn's and colitis organisation [ECCO]: third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1. J Crohns Colitis. 2017 Apr;11(6) :649-70.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>131024</offset><text>Annese V, Beaugerie L, Egan L, et al. European evidence-based consensus: inflammatory bowel disease and malignancies. J Crohns Colitis. 2015 Nov;9(11):945-65.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>131183</offset><text>The Japanese Society of Gastroenterology guideline, evidence-based clinical guidelines for inflammatory bowel disease (IBD). 2nd ed. The Japanese Society of Gastroenterology; 2020 [cited 2021 Dec 15]. Available from: . Japanese.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>131412</offset><text>Uchino M, Ikeuchi H, Hata K, et al. Intestinal cancer in patients with Crohn's disease: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2021 Nov;36(2):329-36.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>131587</offset><text>Lyakhovich A, Gasche C. Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine. Aliment Pharmacol Ther. 2010 Jan 15;31(2):202-9.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>131745</offset><text>O'Connor A, Packey CD, Akbari M, et al. Mesalamine, but not sulfasalazine, reduces the risk of colorectal neoplasia in patients with inflammatory bowel disease: an agent-specific systematic review and meta-analysis. Inflamm Bowel Dis. 2015 Apr;21(11):2562-9.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>132004</offset><text>Qiu X, Ma J, Wang K, et al. Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis. Oncotarget. 2017 Jan 3;8(1):1031-45.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>132232</offset><text>Bonovas S, Fiorino G, Lytras T, et al. Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017 Oct;45(9):1179-92.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>132461</offset><text>Zhao LN, Li JY, Yu T, et al. 5-aminosalicylates reduce the risk of colorectal neoplasia in patients with ulcerative colitis: an updated meta-analysis. PLoS One. 2014 Apr;9(4):e94208.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>132644</offset><text>Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005 Aug;100(6):1345-53.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>132860</offset><text>Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease. Cochrane Database Syst Rev. 2016 Jan;9:CD003715.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>133027</offset><text>Zhu Z, Mei Z, Guo Y, et al. Reduced risk of inflammatory bowel disease-associated colorectal neoplasia with use of thiopurines: a systematic review and meta-analysis. J Crohns Colitis. 2018 Apr;12(5):546-58.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>133235</offset><text>Lu MJ, Qiu XY, Mao XQ, et al. Systematic review with meta-analysis: thiopurines decrease the risk of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2018 Oct;47(3):318-31.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>133449</offset><text>Gong J, Zhu L, Guo Z, et al. Use of thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel diseases: a meta-analysis. PLoS One. 2013 Nov 28;8(11):e81487.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>133629</offset><text>Jess T, Lopez A, Andersson M, et al. Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis. Clin Gastroenterol Hepatol. 2014 Nov;12(11):1793-800.e1.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>133830</offset><text>Pardi DS, Loftus EV Jr, Kremers WK, et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology. 2003 Apr;124(4):889-93.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>134035</offset><text>Eaton JE, Silveira MG, Pardi DS, et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol. 2011 Sep;106(9):1638-45.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>134282</offset><text>Hansen JD, Kumar S, Lo WK, et al. Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis. Dig Dis Sci. 2013 Nov;58(11):3079-87.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>134486</offset><text>Charkaoui M, Hajage D, Tubach F, et al. Impact of anti-tumour necrosis factor agents on the risk of colorectal cancer in patients with ulcerative colitis: nationwide French cohort study. J Crohns Colitis. 2022 Jul 14;16(6):893-9.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>134716</offset><text>Alkhayyat M, Abureesh M, Gill A, et al. Lower rates of colorectal cancer in patients with inflammatory bowel disease using anti-TNF therapy. Inflamm Bowel Dis. 2021 Jun 15;27(7):1052-60.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>134903</offset><text>Baars JE, Looman CW, Steyerberg EW, et al. The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study. Am J Gastroenterol. 2011 Feb;106(2):319-28.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>135123</offset><text>Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010 Nov 20;376(9754):1741-50.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>135321</offset><text>Burr NE, Hull MA, Subramanian V. Does aspirin or non-aspirin non-steroidal anti-inflammatory drug use prevent colorectal cancer in inflammatory bowel disease? World J Gastroenterol. 2016 Apr 7;22(13):3679-86.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>135530</offset><text>Shah SC, Glass J, Giustino G, et al. Statin exposure is not associated with reduced prevalence of colorectal neoplasia in patients with inflammatory bowel disease. Gut Liver. 2019 Jan 15;13(1):54-61.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>135730</offset><text>Burr NE, Hull MA, Subramanian V. Folic acid supplementation may reduce colorectal cancer risk in patients with inflammatory bowel disease: a systematic review and meta-analysis. J Clin Gastroenterol. 2017 Mar;51(3):247-53.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>135953</offset><text>Löfberg R, Broström O, Karlén P, et al. Colonoscopic surveillance in long-standing total ulcerative colitis―a 15-year follow-up study. Gastroenterology. 1990 Oct;99(4):1021-31.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>136135</offset><text>Lutgens MW, Oldenburg B, Siersema PD, et al. Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease. Br J Cancer. 2009 Nov 17;101(10):1671-5.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>136330</offset><text>Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther. 2000 Feb;14(2):145-53.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>136486</offset><text>Ananthakrishnan AN, Cagan A, Cai T, et al. Colonoscopy is associated with a reduced risk for colon cancer and mortality in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2015 Feb;13(2):322-9.e1.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>136705</offset><text>Farraye FA, Odze RD, Eaden J, et al. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010 Feb;138(2):746-74, 774:e1-4.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>136902</offset><text>Itzkowitz SH, Present DH, Crohn's and Colitis Foundation of America Colon Cancer in IBD Study Group. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2005 Mar;11(3):314-21.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>137143</offset><text>American Society for Gastrointestinal Endoscopy Standards of Practice Committee; Shergill AK, Lightdale JR, et al. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc. 2015 May;81(5):1101-21.e1-13.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>137362</offset><text>Kornbluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010 Mar;105(3):501-24.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>137624</offset><text>Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010 May;59(5):666-89.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>137810</offset><text>Annese V, Daperno M, Rutter MD, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013 Dec;7(12):982-1018.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>137971</offset><text>Laine L, Kaltenbach T, Barkun A, et al. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastroenterology. 2015 Mar;148(3):639-51.e28.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>138173</offset><text>Bye WA, Nguyen TM, Parker CE, et al. Strategies for detecting colon cancer in patients with inflammatory bowel disease. Cochrane Database Syst Rev. 2017 Sep 18;9(9):CD000279.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>138348</offset><text>Choi PM, Nugent FW, Schoetz DJ Jr, et al. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology. 1993 Aug;105(2):418-24.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>138522</offset><text>Lashner BA, Kane SV, Hanauer SB. Colon cancer surveillance in chronic ulcerative colitis: historical cohort study. Am J Gastroenterol. 1990 Sep;85(9):1083-7.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>138680</offset><text>Rabbenou W, Ullman TA. Risk of colon cancer and recommended surveillance strategies in patients with ulcerative colitis. Gastroenterol Clin North Am. 2020 Dec;49(4):791-807.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>138854</offset><text>Lindberg BU, Broomé U, Persson B. Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. Dis Colon Rectum. 2001 Jan;44(1):77-85.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>139099</offset><text>Sengupta N, Yee E, Feuerstein JD. Colorectal cancer screening in inflammatory bowel disease. Dig Dis Sci. 2016 Apr;61(4):980-9.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>139227</offset><text>Kim HS, Hernaez R, Sansgiry S, et al. Comparative effectiveness of surveillance colonoscopy intervals on colorectal cancer outcomes in a national cohort of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2022 Dec;20(12):2848-57.e2.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>139481</offset><text>Stolwijk JA, Langers AM, Hardwick JC, et al. A thirty-year follow-up surveillance study for neoplasia of a Dutch ulcerative colitis cohort. ScientificWorldJournal. 2013 Nov 28;2013:274715.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>139670</offset><text>Sekra A, Schauer C, Mills L, et al. Chromoendoscopy versus standard colonoscopy for detection of nonpolypoid dysplasia in patients with inflammatory bowel disease. N Z Med J. 2018 Jul 13;131(1478):32-8.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>139873</offset><text>Moussata D, Allez M, Cazals-Hatem D, et al. Are random biopsies still useful for the detection of neoplasia in patients with IBD undergoing surveillance colonoscopy with chromoendoscopy? Gut. 2018 Apr;67(4):616-24.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>140088</offset><text>Bisschops R, Bessissow T, Joseph JA, et al. Chromoendoscopy versus narrow band imaging in UC: a prospective randomised controlled trial. Gut. 2018 Jun;67(6):1087-94.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>140254</offset><text>Iannone A, Ruospo M, Wong G, et al. Chromoendoscopy for surveillance in ulcerative colitis and Crohn's disease: a systematic review of randomized trials. Clin Gastroenterol Hepatol. 2017 Nov;15(11):1684-97.e11.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>140465</offset><text>Sugita A. Evaluation of a Surveillance Program for Anorectal Cancer (including fistula-associated cancer) in Crohn's disease. Report on a grant from the Ministry of Health, Labour and Welfare (Research Project on Intractable Diseases): research on intractable inflammatory bowel diseases (co-investigator's report); 2020. (Japanese). Characteristics and prognosis of small and large intestinal cancers associated with ulcerative colitis and Crohn's disease - Report No. 15.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>140939</offset><text>Yoshizawa S, Matsuoka K, Inoue N, et al. Clinical significance of serum p53 antibodies in patients with ulcerative colitis and its carcinogenesis. Inflamm Bowel Dis. 2007 Jul;13(7):865-73.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>141128</offset><text>Hirano Y, Futami K, Higashi D, et al. Anorectal cancer surveillance in Crohn's disease. J Anus Rectum Colon. 2018 Oct 29;2(4):145-54.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>141262</offset><text>Viennot S, Deleporte A, Moussata D, et al. Colon cancer in inflammatory bowel disease: recent trends, questions and answers. Gastroenterol Clin Biol. 2009 Jun:33(suppl 3):S190-201.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>141443</offset><text>Johnson DH, Taylor WR, Aboelsoud MM, et al. DNA methylation and mutation of small colonic neoplasms in ulcerative colitis and Crohn's colitis: implications for surveillance. Inflamm Bowel Dis. 2016 Jul;22(7):1559-67.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>141660</offset><text>Mooiweer E, Fidder HH, Siersema PD, et al. Fecal calprotectin testing can identify ineffective colorectal cancer surveillance procedures in patients with longstanding colitis. Inflamm Bowel Dis. 2014 Jun;20(6):1079-84.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>141879</offset><text>Eaden J, Abrams K, Shears J, et al. Randomized controlled trial comparing the efficacy of a video and information leaflet versus information leaflet alone on patient knowledge about surveillance and cancer risk in ulcerative colitis. Inflamm Bowel Dis. 2002 Nov;8(6):407-12.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>142154</offset><text>Watanabe T, Ajioka Y, Mitsuyama K, et al. Comparison of targeted vs random biopsies for surveillance of ulcerative colitis-associated colorectal cancer. Gastroenterology. 2016 Dec;151(6):1122-30.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>142350</offset><text>Watanabe K, Hida N, Ajioka Y, et al. Photodynamic diagnosis of endoscopically invisible flat dysplasia in patients with ulcerative colitis by visualization using local 5-aminolevulinic acid-induced photosensitization. Gastrointest Endosc. 2010 May;71(6):1094-6.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>142612</offset><text>Hata K, Ishihara S, Ajioka Y, et al. Long-term follow-up of targeted biopsy yield (LOFTY study) in ulcerative colitis surveillance colonoscopy. J Clin Med. 2020 Jul 18;9(7):2286.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>142791</offset><text>Torres J, Caprioli F, Katsanos KH, et al. Predicting outcomes to optimize disease management in inflammatory bowel diseases. J Crohns Colitis. 2016 Dec;10(12):1385-94.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>142959</offset><text>Ueda T, Inoue T, Nakamoto T, et al. Anorectal cancer in Crohn's disease has a poor prognosis due to its advanced stage and aggressive histological features: a systematic literature review of Japanese patients. J Gastrointest Cancer. 2020 Mar;51(1):1-9.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>143212</offset><text>Choi PM, Zelig MP. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut. 1994 Jul;35(7):950-4.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>143381</offset><text>Stahl TJ, Schoetz DJ Jr, Roberts PL, et al. Crohn's disease and carcinoma: increasing justification for surveillance? Dis Colon Rectum. 1992 Sep;35(9):850-6.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>143539</offset><text>Higashi D, Katsuno H, Kimura H, et al. Current state of and problems related to cancer of the intestinal tract associated with Crohn's disease in Japan. Anticancer Res. 2016 Jul;36(7):3761-6.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>143731</offset><text>Van Assche G, Dignass A, Bokemeyer B, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis. 2013 Feb;7(1):1-33.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>143937</offset><text>Matsumoto T, Iwao Y, Igarashi M, et al. Endoscopic and Chromoendoscopic atlas featuring dysplastic lesions in surveillance colonoscopy for patients with long-standing ulcerative colitis. Inflamm Bowel Dis. 2008 Feb;14(2):259-64.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>144166</offset><text>Farraye FA, Odze RD, Eaden J, et al. AGA Medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010 Feb;138(2):738-45.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>144363</offset><text>Hata K, Watanabe T, Kazama S, et al. Earlier surveillance colonoscopy programme improves survival in patients with ulcerative colitis associated colorectal cancer: results of a 23-year surveillance programme in the Japanese population. Br J Cancer. 2003 Oct 6;89(7):1232-6.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>144637</offset><text>Ikeuchi H, Nakano H, Uchino M, et al. Usefulness of FDG-PET for Crohn's disease. Nippon Daicho Komonbyo Gakkai Zasshi. 2008 Oct;61(6):303-10. Japanese.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>144789</offset><text>Delbeke D, Martin WH. PET and PET-CT for evaluation of colorectal carcinoma. Semin Nucl Med. 2004 Jul;34(3):209-23.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>144905</offset><text>Sato M, Ogawa H, Shibata C, et al. A case of anal cancer with rapidly rising CEA in longstanding perianal Crohn disease after infliximab administration. Nihon Shokakibyo Gakkai Zasshi. 2010 Jun;107(6):885-92. Japanese.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>145124</offset><text>Yano Y, Matsui T, Uno H, et al. Risks and clinical features of colorectal cancer complicating Crohn's disease in Japanese patients. J Gastroenterol Hepatol. 2008 Nov;23(11):1683-8.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>145305</offset><text>Marzo M, Felice C, Pugliese D, et al. Management of perianal fistulas in Crohn's disease: an up-to-date review. World J Gastroenterol. 2015 Feb 7;21(5):1394-403.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>145467</offset><text>Kudo S, Hirota S, Nakajima T, et al. Colorectal tumours and pit pattern. J Clin Pathol. 1994 Oct;47(10):880-5.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>145578</offset><text>Sano Y, Tanaka S, Kudo SE, et al. Narrow-band imaging (NBI) magnifying endoscopic classification of colorectal tumors proposed by the Japan NBI Expert Team. Dig Endosc. 2016 Jul;28(5):526-33.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>145770</offset><text>Iacucci M, Cannatelli R, Tontini GE, et al. Improving the quality of surveillance colonoscopy in inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2019 Dec;4(12):971-83.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>145948</offset><text>Nishiyama S, Oka S, Tanaka S, et al. Clinical usefulness of narrow band imaging magnifying colonoscopy for assessing ulcerative colitis-associated cancer/dysplasia. Endosc Int Open. 2016 Nov;4(11):E1183-7.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>146154</offset><text>Watanabe K, Sogawa M, Yamagami H, et al. Endoscopic differential diagnosis between ulcerative colitis-associated neoplasia and sporadic neoplasia in surveillance colonoscopy using narrow band imaging. Dig Endosc. 2011 May:23(suppl 1):143-9.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>146395</offset><text>Mutaguchi M, Naganuma M, Sugimoto S, et al. Difference in the clinical characteristic and prognosis of colitis-associated cancer and sporadic neoplasia in ulcerative colitis patients. Dig Liver Dis. 2019 Sep;51(9):1257-64.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>146618</offset><text>Iacucci M, McQuaid K, Gui XS, et al. A multimodal (FACILE) classification for optical diagnosis of inflammatory bowel disease associated neoplasia. Endoscopy. 2019 Feb;51(2):133-41.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>146800</offset><text>Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an Update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021 Apr;160(5):1570-83.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>147122</offset><text>Shinagawa T, Hata K, Morikawa T, et al. Pine-cone and villi patterns are endoscopic signs suggestive of ulcerative colitis-associated colorectal cancer and dysplasia. Gastrointest Endosc. 2019 Mar;89(3):565-75.e3.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>147336</offset><text>Murthy SK, Feuerstein JD, Nguyen GC, et al. AGA clinical practice update on endoscopic surveillance and management of colorectal dysplasia in inflammatory bowel diseases: expert review. Gastroenterology. 2021 Sep;161(3):1043-51.e4.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>147568</offset><text>Gui X, Iacucci M, Ghosh S, et al. Revisiting the distinct histomorphologic features of inflammatory bowel disease-associated neoplastic precursor lesions in the SCENIC and post-DALM Era. Hum Pathol. 2020 Jun:100:24-37.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>147787</offset><text>Lang-Schwarz C, Adler W, Geppert M, et al. Sporadic adenoma or ulcerative colitis associated neoplasia? The endoscopist's information has an impact on diagnosis and patient management. Pathol Res Pract. 2020 Nov;216(11):153162.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>148015</offset><text>Parian AM, Lazarev MG. Serrated colorectal lesions in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2018 Jan;14(1):19-25.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>148162</offset><text>Muto T, Wakasa T, Kina I, et al. Histopathological criteria for dysplasia in ulcerative colitis: proposal of new diagnostic criteria for application in surveillance colonoscopy. J Jpn Soc Coloproctol. 1994;47:547-51. Japanese.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>148389</offset><text>Ajioka Y, Tani Y, Takamura K, et al. [Topics in colorectal cancer Pathological diagnosis and carcinogenic mechanisms of inflammation-associated colorectal cancer. Byori to Rinsho]. 2018;36:1076-81. Japanese.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>148597</offset><text>Allende D, Elmessiry M, Hao W, et al. Inter-observer and intra-observer variability in the diagnosis of dysplasia in patients with inflammatory bowel disease: correlation of pathological and endoscopic findings. Colorectal Dis. 2014 Sep;16(9):710-8.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>148847</offset><text>Eaden J, Abrams K, McKay H, et al. Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis. J Pathol. 2001 Jun;194(2):152-7.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>149047</offset><text>Blackstone MO, Riddell RH, Rogers BH, et al. Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: an indication for colectomy. Gastroenterology. 1981 Feb;80(2):366-74.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>149266</offset><text>Lashner BA, Shapiro BD, Husain A, et al. Evaluation of the usefulness of testing for p53 mutations in colorectal cancer surveillance for ulcerative colitis. Am J Gastroenterol. 1999 Feb;94(2):456-62.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>149466</offset><text>Hirsch D, Wangsa D, Zhu YJ, et al. Dynamics of genome alterations in Crohn's disease-associated colorectal carcinogenesis. Clin Cancer Res. 2018 Oct 15;24(20):4997-5011.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>149636</offset><text>Ajioka Y, Iwanaga A, Watanabe J, et al. Carcinogenesis and tumor progression in inflammatory bowel disease: histogenesis of colorectal cancer in ulcerative colitis. Stomach and Intestine (I to Cho). 2008;43:1935-46. Japanese.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>149862</offset><text>Du L, Kim JJ, Shen J, et al. KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis. Oncotarget. 2017 Mar 28;8(13):22175-86.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>150032</offset><text>Lu X, Yu Y, Tan S. p53 expression in patients with ulcerative colitis-associated with dysplasia and carcinoma: a systematic meta-analysis. BMC Gastroenterol. 2017 Oct 25;17(1):111.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>150213</offset><text>Noffsinger AE, Belli JM, Miller MA, et al. A unique basal pattern of p53 expression in ulcerative colitis is associated with mutation in the p53 gene. Histopathology. 2001 Nov;39(5):482-92.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>150403</offset><text>Yokota Y. Evaluation of p53 protein overexpression by immunohistochemistry: A study on the correlation with gene mutations [PhD thesis]. Niigata: Niigata University Graduate School of Medical and Dental Sciences; 2015. Japanese.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>150632</offset><text>Ajioka Y. Immunohistochemical staining for epithelial tumors: immunostaining of colorectal epithelial tumors including UC-associated tumors. Stomach and Intestine (I to Cho). 2017;52:1010-8. Japanese.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>150833</offset><text>Mikami T, Yoshida T, Akino F, et al. Apoptosis regulation differs between ulcerative colitis-associated and sporadic colonic tumors. Association with survivin and bcl-2. Am J Clin Pathol. 2003 May;119(5):723-30.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>151045</offset><text>Andersen SN, Rognum TO, Bakka A, et al. Ki-67: a useful marker for the evaluation of dysplasia in ulcerative colitis. Mol Pathol. 1998 Dec;51(6):327-32.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>151198</offset><text>Zivković V, Petrović A, Dordević B, et al. Computer-assisted quantitative analysis of Ki-67 antigen in dysplasia--associated lesions or masses in ulcerative colitis. Vojnosanit Pregl. 2007 Nov;64(11):753-8.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>151408</offset><text>Mir-Madjlessi SH, Farmer RG, Easley KA, et al. Colorectal and extracolonic malignancy in ulcerative colitis. Cancer. 1986 Oct 1;58(7):1569-74.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>151551</offset><text>Heimann TM, Oh SC, Martinelli G, et al. Colorectal carcinoma associated with ulcerative colitis: a study of prognostic indicators. Am J Surg. 1992 Jul;164(1):13-7.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>151715</offset><text>Sigel JE, Petras RE, Lashner BA, et al. Intestinal adenocarcinoma in Crohn's disease: a report of 30 cases with a focus on coexisting dysplasia. Am J Surg Pathol. 1999 Jun;23(6):651-5.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>151900</offset><text>Suzuki K, Watanabe T, Hata K, et al. Colorectal cancer and surveillance in patients with ulcerative colitis: the Japanese Study. J Jpn Soc Coloproctol. 2003 Oct;56:62-8. Japanese.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>152080</offset><text>Shinozaki M. Crohn's disease and intestinal cancer in Japan. J Jpn Soc Coloproctol. 2008 Oct;61:353-63. Japanese.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>152194</offset><text>Sasaki H, Ikeuchi H, Bando T, et al. Clinicopathological characteristics of cancer associated with Crohn's disease. Surg Today. 2017 Jan;47(1):35-41.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>152344</offset><text>Ajioka Y. Pathological diagnosis of the early lesions of ulcerative colitis-associated carcinogenesis - current status and problems. Nihon Shokakibyo Gakkai Zasshi. 2020 Jan;117(11):957-64. Japanese.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>152544</offset><text>Riddell RH. The precarcinomatous phase of ulcerative colitis. Curr Top Pathol. 1976 Oct;63:179-219.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>152644</offset><text>von Herbay A, Herfarth C, Otto HF. Cancer and dysplasia in ulcerative colitis: a histologic study of 301 surgical specimen. Z Gastroenterol. 1994 Jul;32(7):382-8.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>152807</offset><text>Greenstein AJ, Slater G, Heimann TM, et al. A comparison of multiple synchronous colorectal cancer in ulcerative colitis, familial polyposis coli, and de novo cancer. Ann Surg. 1986 Feb;203(2):123-8.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>153007</offset><text>van Leersum NJ, Aalbers AG, Snijders HS, et al. Synchronous colorectal carcinoma: a risk factor in colorectal cancer surgery. Dis Colon Rectum. 2014 Apr;57(4):460-6.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>153173</offset><text>Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet. 1994 Jan 8;343(8889):71-4.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>153336</offset><text>Uzzan M, Kirchgesner J, Oubaya N, et al. Risk of rectal neoplasia after colectomy and ileorectal anastomosis for ulcerative colitis. J Crohns Colitis. 2017 Aug 1;11(8):930-5.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>153511</offset><text>Derikx LAAP, Nissen LHC, Smits LJT, et al. Risk of neoplasia after colectomy in patients with inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016 Jun;14(6):798-806.e20.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>153728</offset><text>Abdalla M, Landerholm K, Andersson P, et al. Risk of rectal cancer after colectomy for patients with ulcerative colitis: a national cohort study. Clin Gastroenterol Hepatol. 2017 Jul;15(7):1055-60.e2.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>153929</offset><text>Kiran RP, Nisar PJ, Goldblum JR, et al. Dysplasia associated with Crohn's colitis: segmental colectomy or more extended resection? Ann Surg. 2012 Aug;256(2):221-6.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>154093</offset><text>Maser EA, Sachar DB, Kruse D, et al. High rates of metachronous colon cancer or dysplasia after segmental resection or subtotal colectomy in Crohn's colitis. Inflamm Bowel Dis. 2013 Aug;19(9):1827-32.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>154294</offset><text>Fichera A, McCormack R, Rubin MA, et al. Long-term outcome of surgically treated Crohn's colitis: a prospective study. Dis Colon Rectum. 2005 May;48(5):963-9.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>154453</offset><text>Tsunoda A, Talbot IC, Nicholls RJ. Incidence of dysplasia in the anorectal mucosa in patients having restorative proctocolectomy. Br J Surg. 1990 May;77(5):506-8.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>154616</offset><text>Sagayama K, Ikeuchi H, Nishigami T, et al. Incidence of and risk factors for dysplasia in mucosectomy area in ulcerative colitis patients undergoing restorative proctocolectomy. Int J Colorectal Dis. 2007 Apr;22(4):439-43.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>154839</offset><text>Horio Y, Uchino M, Bando T, et al. Incidence, risk factors and outcomes of cancer of the anal transitional zone in patients with ulcerative colitis. J Crohns Colitis. 2020 Nov 7;14(11):1565-71.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>155033</offset><text>Remzi FH, Fazio VW, Delaney CP, et al. Dysplasia of the anal transitional zone after ileal pouch―anal anastomosis: results of prospective evaluation after a minimum of ten years. Dis Colon Rectum. 2003 Jan;46(1):6-13.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>155253</offset><text>Silva-Velazco J, Stocchi L, Wu XR, et al. Twenty-year-old stapled pouches for ulcerative colitis without evidence of rectal cancer: implications for surveillance strategy? Dis Colon Rectum. 2014 Nov;57(11):1275-81.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>155468</offset><text>Hirata A, Ikeuchi H, Bando T, et al. Adenocarcinoma in the anal canal after restorative proctocolectomy with ileal J-pouch for ulcerative colitis. Nippon Shokaki Geka Gakkai zasshi. 2017;50(6):499-505. Japanese.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>155680</offset><text>Lee SW, Sonoda T, Milsom JW. Three cases of adenocarcinoma following restorative proctocolectomy with hand-sewn anastomosis for ulcerative colitis: a review of reported cases in the literature. Colorectal Dis. 2005 Nov;7(6):591-7.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>155911</offset><text>O'Connell PR, Pemberton JH, Weiland LH, et al. Does rectal mucosa regenerate after ileoanal anastomosis? Dis Colon Rectum. 1987 Jan;30(1):1-5.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>156054</offset><text>Rodriguez-Sanjuan JC, Polavieja MG, Naranjo A, et al. Adenocarcinoma in an ileal pouch for ulcerative colitis. Dis Colon Rectum. 1995 Jul;38(7):779-80.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>156206</offset><text>Block M, Börjesson L, Willén R, et al. Neoplasia in the colorectal specimens of patients with ulcerative colitis and ileal pouch-anal anastomosis-need for routine surveillance? Scand J Gastroenterol. 2015 May;50(5):528-35.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>156431</offset><text>Schluender SJ, Mei L, Yang H, et al. Can a meta-analysis answer the question: is mucosectomy and handsewn or double-stapled anastomosis better in ileal pouch-anal anastomosis? Am Surg. 2006 Oct;72(10):912-6.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>156639</offset><text>Horio Y, Uchino M, Bando T, et al. Association between higher body mass index and pouch-related complications during restorative proctocolectomy in patients with ulcerative colitis. Digestion. 2018;98(4):257-62.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>156851</offset><text>Hardt J, Kienle P. Occult and manifest colorectal carcinoma in ulcerative colitis: how dose it influence surgical decision making? Viszeralmedizin. 2015 Aug;31(4):252-7.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>157021</offset><text>Suzuki N, Toyonaga T, East JE. Endoscopic submucosal dissection of colitis-related dysplasia. Endoscopy. 2017 Dec;49(12):1237-42.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>157151</offset><text>Sensi B, Bagaglini G, Bellato V, et al. Management of low rectal cancer complicating ulcerative colitis: proposal of a treatment algorithm. Cancers (Basel). 2021 May 13;13(10):2350.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>157333</offset><text>Hotta S, Shimada Y, Nakano M, et al. Feasibility of restorative proctocolectomy in patients with ulcerative colitis-associated lower rectal cancer: a retrospective study. Asian J Surg. 2019 Jan;42(1):267-73.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>157541</offset><text>Merchea A, Wolff BG, Dozois EJ, et al. Clinical features and oncologic outcomes in patients with rectal cancer and ulcerative colitis: a single-institution experience. Dis Colon Rectum. 2012 Aug;55(8):881-5.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>157749</offset><text>Gorfine SR, Harris MT, Bub DS, et al. Restorative proctocolectomy for ulcerative colitis complicated by colorectal cancer. Dis Colon Rectum. 2004 Aug;47(8):1377-85.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>157914</offset><text>Inoue Y, Araki T, Okugawa Y, et al. Chemoradiotherapy followed by restorative proctocolectomy with partial intersphincteric resection for advanced rectal cancer associated with ulcerative colitis: report of a case. Surg Today. 2014 Feb;44(2):387-90.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>158164</offset><text>Sugita A, Koganei K, Tatsumi K, et al. Management of rectal cancer including cancer in the anal fistula with Crohn's disease. Nihon Shokakibyo Gakkai Zasshi. 2013 Mar;110(3):396-402. Japanese.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>158357</offset><text>Futami K, Higashi D, Futatsuki R, et al. Long-term strategy of surgical treatment for intestinal Crohn's disease in long term. Nihon Shokakibyo Gakkai Zasshi. 2011 Mar;108(3):410-7.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>158539</offset><text>Treatment Guideline for Crohn's disease. Proposed diagnostic criteria and treatment for ulcerative colitis and Crohn's disease. Annual reports of 2020. Intractable diseases, the health and labour sciences research grants (chief researchers: Dr T. Hisamatsu) from the Ministry of Health, Labor and Welfare of Japan. 2021:30-6.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>158865</offset><text>Kuwahara R, Ikeuchi H, Minagawa T, et al. Clinical results following intestinal resection in 1,143 patients with Crohn disease. Jpn J Gastroenterol Surg. 2018;51(11):671-9.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>159038</offset><text>Higashi D, Futami K, Egawa Y, et al. Prevention and countermeasures for suture failure in patient with Crohn's disease. J Jpn Soc Coloproctol. 2009;62(10):818-22.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>159201</offset><text>Kuroki H, Sugita A, Koganei K, et al. Clinicopathological and prognostic evaluations of anorectal cancer after fecal diversion for patients with Crohn's disease. BMC Gastroenterol. 2021 Apr 13;21(1):168.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>159405</offset><text>Widmar M, Greenstein AJ, Sachar DB, et al. Small bowel adenocarcinoma in Crohn's disease. J Gastrointest Surg. 2011 May;15(5):797-802.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>159540</offset><text>Hussain T, Jeganathan NA, Karagkounis G, et al. Small bowel adenocarcinoma in Crohn's disease: a rare but devastating complication. Tech Coloproctol. 2020 Oct;24(10):1055-62.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>159715</offset><text>Wieghard N, Mongoue-Tchokote S, Young JI, et al. Prognosis of small bowel adenocarcinoma in Crohn's disease compares favourably with de novo small bowel adenocarcinoma. Colorectal Dis. 2017 May;19(5):446-55.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>159923</offset><text>Fields AC, Hu FY, Lu P, et al. Small bowel adenocarcinoma: is there a difference in survival for Crohn's versus sporadic cases? J Crohns Colitis. 2020 Mar 13;14(3):303-8.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>160094</offset><text>Svrcek M, Piton G, Cosnes J, et al. Small bowel adenocarcinomas complicating Crohn's disease are associated with dysplasia: a pathological and molecular study. Inflamm Bowel Dis. 2014 Sep;20(9):1584-92.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>160297</offset><text>Cahill C, Gordon PH, Petrucci A, et al. Small bowel adenocarcinoma and Crohn's disease: any further ahead than 50 years ago? World J Gastroenterol. 2014 Sep 7;20(33):11486-95.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>160473</offset><text>Spinelli A, Bonovas S, Burisch J, et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. J Crohns Colitis. 2022 Feb 23;16(2):179-89.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>160633</offset><text>Holubar SD, Lightner AL, Poylin V, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Ulcerative Colitis. Dis Colon Rectum. 2021 Jul 1;64(7):783-804.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>160849</offset><text>Academic Committee of the Japan Society for Endoscopic Surgery (JSES). Tokyo: General Incorporated Association Japan Society for Endoscopic Surgery; 2021. The 15th national survey of endoscopic surgery: report on the results of the survey; p. 149. Japanese.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>161107</offset><text>Japanese Society for Cancer of the Colon and Rectum. Edition. Tokyo: Kanehara Shuppan; 2020. Hereditary colorectal cancer; p. 133. (Japanese) Guideline 2020.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>161265</offset><text>Japan Society for Endoscopic Surgery. Endoscopic surgery guidelines for certified surgeons; 2019 Edition. Japanese.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>161381</offset><text>Singh P, Bhangu A, Nicholls RJ, et al. A systematic review and meta-analysis of laparoscopic vs open restorative proctocolectomy. Colorectal Dis. 2013 Jul;15(7):e340-51.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>161551</offset><text>Hull TL, Joyce MR, Geisler DP, et al. Adhesions after laparoscopic and open ileal pouch-anal anastomosis surgery for ulcerative colitis. Br J Surg. 2012 Feb;99(2):270-5.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>161721</offset><text>Lavryk OA, Stocchi L, Ashburn JH, et al. Case-matched comparison of long-term functional and quality of life outcomes following laparoscopic versus open ileal pouch-anal anastomosis. World J Surg. 2018 Nov;42(11):3746-54.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>161943</offset><text>Flynn J, Larach JT, Kong JCH, et al. Robotic versus laparoscopic ileal pouch-anal anastomosis (IPAA): a systematic review and meta-analysis. Int J Colorectal Dis. 2021 Jul;36(7):1345-56.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>162130</offset><text>Lightner AL, Grass F, McKenna NP, et al. Short-term postoperative outcomes following robotic versus laparoscopic ileal pouch-anal anastomosis are equivalent. Tech Coloproctol. 2019 Mar;23(3):259-66.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>162329</offset><text>Chandrasinghe P, Carvello M, Wasmann K, et al. Transanal ileal pouch-anal anastomosis for ulcerative colitis has comparable long-term functional outcomes to transabdominal approach: A Multicentre Comparative Study. J Crohns Colitis. 2020 Jul 9;14(6):726-33.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>162587</offset><text>Fleshman J, Branda M, Sargent DJ, et al. Effect of laparoscopic-assisted resection vs open resection of Stage II or III rectal cancer on pathologic outcomes: the ACOSOG Z6051 randomized clinical trial. JAMA. 2015 Oct 6;314(13):1346-55.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>162823</offset><text>Stevenson ARL, Solomon MJ, Lumley JW, et al. Effect of laparoscopic-assisted resection vs open resection on pathological outcomes in rectal cancer: the ALaCaRT randomized clinical trial. JAMA. 2015 Oct 6;314(13):1356-63.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>163044</offset><text>Bemelman WA, Warusavitarne J, Sampietro GM, et al. ECCO-ESCP consensus on surgery for Crohn's disease. J Crohns Colitis. 2018 Jan 5;12(1):1-16.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>163188</offset><text>Lightner AL, Vogel JD, Carmichael JC, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the surgical management of Crohn's disease. Dis Colon Rectum. 2020 Aug;63(8):1028-52.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>163402</offset><text>Maartense S, Dunker MS, Slors JFM, et al. Laparoscopic-assisted versus open ileocolic resection for Crohn's disease: a randomized trial. Ann Surg. 2006 Feb;243(2):143-53.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>163573</offset><text>Milsom JW, Hammerhofer KA, Böhm B, et al. Prospective, randomized trial comparing laparoscopic vs. conventional surgery for refractory ileocolic Crohn's disease. Dis Colon Rectum. 2001 Jan;44(1):1-9.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>163774</offset><text>Raskin ER, Gorrepati ML, Mehendale S, et al. Robotic-assisted ileocolic resection for Crohn's disease: outcomes from an early national experience. J Robot Surg. 2019 Jun;13(3):429-34.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>163958</offset><text>Tran TB, Qadan M, Dua MM, et al. Prognostic relevance of lymph node ratio and total lymph node count for small bowel adenocarcinoma. Surgery. 2015 Aug;158(2):486-93.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>164124</offset><text>Kitano S, Inomata M, Mizusawa J, et al. Survival outcomes following laparoscopic versus open D3 dissection for stage II or III colon cancer (JCOG0404): a phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2017 Apr;2(4):261-8.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>164367</offset><text>Bonjer HJ, Deijen CL, Haglind E, et al. A randomized trial of laparoscopic versus open surgery for rectal cancer. N Engl J Med. 2015 Jul 9;373(2):194.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>164518</offset><text>Laine L, Kaltenbach T, Barkun A, et al. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastrointest Endosc. 2015 Mar;81(3):489-501.e26.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>164723</offset><text>Matsumoto K, Kawasaki K. Surveillance for ulcerative colitis―overview and issues of the SCENIC international consensus statement. Itocho. 2020;55:191-9. Japanese.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>164888</offset><text>Tanaka S, Kashida H, Saito Y, et al. Japan Gastroenterological Endoscopy Society guidelines for colorectal endoscopic submucosal dissection/endoscopic mucosal resection. Dig Endosc. 2020 Jan;32(2):219-39.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>165093</offset><text>Kinoshita S, Nishizawa T, Yahagi N, et al. Endoscopic submucosal dissection in patients with ulcerative colitis. Digestion. 2019;99(1):27-32.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>165235</offset><text>Uraoka T, Hashimoto Y, Sato K, et al. Endoscopic treatment for ulcerative colitis-associated tumors―my perspective. Itocho. 2020;55:170-1. Japanese.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>165386</offset><text>Iacopini F, Saito Y, Yamada M, et al. Curative endoscopic submucosal dissection of large nonpolypoid superficial neoplasms in ulcerative colitis (with videos). Gastrointest Endosc. 2015;82(4):734-8.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>165585</offset><text>Kinoshita S, Uraoka T, Nishizawa T, et al. The role of colorectal endoscopic submucosal dissection in patients with ulcerative colitis. Gastrointest Endosc. 2018 Apr;87(4):1079-84.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>165766</offset><text>Yang DH, Kim J, Song EM, et al. Outcomes of ulcerative colitis-associated dysplasia patients referred for potential endoscopic submucosal dissection. J Gastroenterol Hepatol. 2019 Sep;34(9):1581-9.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>165964</offset><text>Matsumoto K, Oka S, Tanaka S, et al. Long-term outcomes after endoscopic submucosal dissection for ulcerative colitis-associated dysplasia. Digestion. 2021;102(2):205-15.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>166135</offset><text>Manta R, Zullo A, Telesca DA, et al. Endoscopic submucosal dissection for visible dysplasia treatment in ulcerative colitis patients: cases series and systematic review of literature. J Crohns Colitis. 2021 Jan 13;15(1):165-8.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>166362</offset><text>Yoshii S, Shinzaki S, Hayashi Y, et al. Endoscopic submucosal dissection for remnant rectal neoplasm after ileal pouch-anal anastomosis for ulcerative colitis. Endoscopy. 2019 Dec;51(12):E406-7.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>166557</offset><text>Chen W, Zhang YL, Zhao Y, et al. Endoscopic resection for non-polypoid dysplasia in inflammatory bowel disease: a systematic review and meta-analysis. Surg Endosc. 2021 Apr;35(4):1534-43.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>166745</offset><text>Wanders LK, Dekker E, Pullens B, et al. Cancer risk after resection of polypoid dysplasia in patients with longstanding ulcerative colitis: a meta-analysis. Clin Gastroenterol Hepatol. 2014 May;12(5):756-64.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>166953</offset><text>Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs. 2007;67(8):1167-98.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>167108</offset><text>Axelrad J, Bernheim O, Colombel JF, et al. Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016 Jan;14(1):58-64.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>167365</offset><text>Shelton E, Laharie D, Scott FI, et al. Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology. 2016 Jul;151(1):97-109.e4.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>167588</offset><text>Micic D, Komaki Y, Alavanja A, et al. Risk of cancer recurrence among individuals exposed to antitumor necrosis factor therapy: a systematic review and meta-analysis of observational studies. J Clin Gastroenterol. 2019 Jan;53(1):e1-11.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>167824</offset><text>Jensen AØ, Thomsen HF, Engebjerg MC, et al. Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-based case-control study. Br J Cancer. 2009;100:200-5.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>168017</offset><text>Sørensen HT, Mellemkjaer L, Nielsen GL, et al. Skin cancers and non-Hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst. 2004 May 5;96(9):709-11.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>168222</offset><text>Radice E, Nelson H, Devine RM, et al. Ileal pouch-anal anastomosis in patients with colorectal cancer: long-term functional and oncologic outcomes. Dis Colon Rectum. 1998 Jan;41(1):11-7.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>168409</offset><text>Ouaïssi M, Maggiori L, Alves A, et al. Colorectal cancer complicating inflammatory bowel disease: a comparative study of Crohn's disease vs ulcerative colitis in 34 patients. Colorectal Dis. 2011 Jun;13(6):684-8.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>168623</offset><text>Alsughayer A, Grass F, McKenna NP, et al. Does IBD portend worse outcomes in patients with rectal cancer? A case-matched analysis IBID. Dis Colon Rectum. 2020;63(9):1265-75.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>168797</offset><text>Nio K, Higashi D, Kumagai H, et al. Efficacy and safety analysis of chemotherapy for advanced colitis-associated colorectal cancer in Japan. Anti Cancer Drugs. 2016 Jun;27(5):457-63.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>168980</offset><text>Coelho R, Silva M, Gaspar R, et al. “A book should not be judged by its cover”: two cases of intestinal adenocarcinoma as the first manifestation of Crohn's disease. Int J Colorectal Dis. 2016 May;31(5):1061-2.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>169195</offset><text>Japanese Society for Cancer of the Colon and Rectum (JSCCR). Japanese guidelines for the treatment of colorectal cancer; 2019 Edition. Tokyo: Kanehara Shuppan; 2019. Japanese.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>169371</offset><text>Yaeger R, Paroder V, Bates DDB, et al. Systemic chemotherapy for metastatic colitis-associated cancer has a worse outcome than sporadic colorectal cancer: Matched case cohort analysis. Clin Colorectal Cancer. 2020 Dec;19(4):e151-6.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>169603</offset><text>Axelrad J, Kriplani A, Ozbek U, et al. Chemotherapy tolerance and oncologic outcomes in patients with colorectal cancer with and without inflammatory bowel disease. Clin Colorectal Cancer. 2017 Sep;16(3):e205-10.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>169816</offset><text>Luo C, Cen S, Ding G, et al. Mucinous colorectal adenocarcinoma: clinical pathology and treatment options. Cancer Commun (Lond). 2019 Mar 29;39(1):13.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>169967</offset><text>Naito A, Mizushima T, Takeyama H, et al. Feasibility of chemotherapy in patients with inflammatory bowel disease-related gastrointestinal cancer. Hepatogastroenterology. 2014 Jun;61(132):942-6.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>170161</offset><text>Goessling W, Mayer RJ. Systemic treatment of patients who have colorectal cancer and inflammatory bowel disease. Gastroenterol Clin North Am. 2006 Sep;35(3):713-27.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>170326</offset><text>Jauregui-Amezaga A, Vermeire S, Prenen H. Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer. Ann Gastroenterol. 2016 Apr-Jun;29(2):127-36.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>170505</offset><text>Bosch SL, van Rooijen SJ, Bökkerink GM, et al. Acute toxicity and surgical complications after preoperative (chemo)radiation therapy for rectal cancer in patients with inflammatory bowel disease. Radiother Oncol. 2017 Apr;123(1):147-53.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>170743</offset><text>Ikeuchi H, Uchino M, Matsuoka H, et al. IBD-associated cancer in rectum and perianal lesion of Crohn's disease patients. IBID. Res. 2010;4:107-12. Japanese.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>170900</offset><text>Araki T, Inoue Y, Tanaka K, et al. Surgery for rectal and anal canal cancer with ulcerative colitis. Nihon Rinsho. 2012 Feb;70(suppl 1):535-40.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>171044</offset><text>Kinoshita O, Nakanishi M, Murayama Y, et al. A Crohn's disease patient with fistula-associated anorectal cancer curatively resected after neoadjuvant chemoradiotherapy. Jpn J Gastroenterol Surg. 2013;46(6):463-70. Japanese.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>171268</offset><text>Iesalnieks I, Gaertner WB, Glass H, et al. Fistula-associated anal adenocarcinoma in Crohn's disease. Inflamm Bowel Dis. 2010 Oct;16(10):1643-8.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>171413</offset><text>Scharl M, Frei P, Frei SM, et al. Epithelial-to-mesenchymal transition in a fistula-associated anal adenocarcinoma in a patient with long-standing Crohn's disease. Eur J Gastroenterol Hepatol. 2014 Jan;26(1):114-8.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>171628</offset><text>Green S, Stock RG, Greenstein AJ. Rectal cancer and inflammatory bowel disease: natural history and implications for radiation therapy. Int J Radiat Oncol Biol Phys. 1999 Jul 1;44(4):835-40.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>171819</offset><text>Althumairi AA, Canner JK, Gearhart SL, et al. Predictors of perineal wound complications and prolonged time to perineal wound healing after abdominoperineal resection. World J Surg. 2016 Jul;40(7):1755-62.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>172025</offset><text>Hultén L. Conversion of a pelvic pouch to a continent pouch (Kock pouch). Tech Coloproctol. 2001 Dec;5(3):192.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>172137</offset><text>Wu XR, Kiran RP, Remzi FH, et al. Preoperative pelvic radiation increases the risk for ileal pouch failure in patients with colitis-associated colorectal cancer. J Crohns Colitis. 2013 Nov;7(10):e419-26.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>172341</offset><text>Ali RA, Dooley C, Comber H, et al. Clinical features, treatment, and survival of patients with colorectal cancer with or without inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011 Jul;9(7):584-9.e1-2.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>172552</offset><text>Reynolds IS, O'Toole A, Deasy J, et al. A meta-analysis of the clinicopathological characteristics and survival outcomes of inflammatory bowel disease associated colorectal cancer. Int J Colorectal Dis. 2017 Apr;32(4):443-51.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>172778</offset><text>Ou B, Zhao J, Guan S, et al. Survival of colorectal cancer in patients with or without inflammatory bowel disease: a meta-analysis. Dig Dis Sci. 2016 Mar;61(3):881-9.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>172945</offset><text>Lu C, Schardey J, Zhang T, et al. Survival outcomes and clinicopathological features in inflammatory bowel disease-associated colorectal cancer: a systematic review and meta-analysis. Ann Surg. 2022 Nov 1;276(5):e319-30.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>173166</offset><text>Olén O, Erichsen R, Sachs MC, et al. Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study. Lancet. 2020 Jan 11;395(10218):123-31.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>173330</offset><text>Svrcek M, Borralho Nunes P, Villanacci V, et al. Clinicopathological and molecular specificities of inflammatory bowel disease-related colorectal neoplastic lesions: The role of inflammation. J Crohns Colitis. 2018 Nov 28;12(12):1486-98.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>173568</offset><text>Yasukawa S, Matsui T, Yano Y, et al. Crohn's disease-specific mortality: a 30-year cohort study at a tertiary referral center in Japan. J Gastroenterol. 2019 Jan;54(1):42-52.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>173743</offset><text>Chin YH, Jain SR, Lee MH, et al. Small bowel adenocarcinoma in Crohn's disease: a systematic review and meta-analysis of the prevalence, manifestation, histopathology, and outcomes. Int J Colorectal Dis. 2022 Jan;37(1):239-50.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>173970</offset><text>Pedersen N, Duricova D, Elkjaer M, et al. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol. 2010 Jul;105(7):1480-7.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>174169</offset><text>Lo B, Zhao M, Vind I, et al. The risk of extraintestinal cancer in inflammatory bowel disease: a systematic review and meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2021 Jun;19(6):1117-38.e19.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>174394</offset><text>Trivedi PJ, Crothers H, Mytton J, et al. Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel disease, based on sex, race, and age. Gastroenterology. 2020 Sep;159(3):915-28.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>174620</offset><text>Askling J, Brandt L, Lapidus A, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut. 2005 May;54(5):617-22.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>174762</offset><text>Armstrong RG, West J, Card TR. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. Am J Gastroenterol. 2010 Jul;105(7):1604-9.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>174951</offset><text>Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009 Nov 7;374(9701):1617-25.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>175170</offset><text>Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017 Nov 7;318(17):1679-86.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>175416</offset><text>Kobayashi T, Uda A, Udagawa E, et al. Lack of increased risk of lymphoma by thiopurines or biologics in Japanese patients with inflammatory bowel disease: a large-scale administrative database analysis. J Crohns Colitis. 2020 Jun 19;14(5):617-23.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>175663</offset><text>van den Heuvel TR, Wintjens DS, Jeuring SF, et al. Inflammatory bowel disease, cancer and medication: cancer risk in the Dutch population-based IBDSL cohort. Int J Cancer. 2016 Sep 15;139(6):1270-80.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>175863</offset><text>Yadav S, Singh S, Harmsen WS, et al. Effect of medications on risk of cancer in patients with inflammatory bowel diseases: a population-based cohort study from Olmsted County, Minnesota. Mayo Clin Proc. 2015 Jun;90(6):738-46.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>176089</offset><text>Singh S, Nagpal SJ, Murad MH, et al. Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014;12(2):210-8.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">ref</infon><offset>176288</offset><text>Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012 Aug;143(2):390-9.e1.</text></passage></document>
</collection>